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General introduction: 
Unraveling OA-related synovial fibrosis: 
A step closer to solving joint stiffness 
& Outline of this thesis
 D.F.G. Remst1 · E.N. Blaney Davidson1 · P.M. van der Kraan1
1. Experimental Rheumatology, Radboud university medical center, Nijmegen, 
The Netherlands. 
8Abstract 
Synovial fibrosis is often found in osteoarthritis (OA), contributing heavily to joint pain and 
joint stiffness, the main symptoms of OA. At this moment the underlying  mechanism of 
OA-related synovial fibrosis is not known and there is no cure available. 
In this review we discuss factors which have been reported to be involved in synovial 
fibrosis. This to get more insight in how these factors contribute to the fibrotic process and 
which would be the best targets for therapy in synovial fibrosis. 
In this regard the following factors are discussed: Transforming growth factor beta 
(TGFβ), Connective Tissue Growth Factor (CTGF), procollagen-lysine,  2-oxoglutarate 
 5-dioxygenase 2 (PLOD2), Tissue inhibitor of metalloproteinase 1 (TIMP-1),  urotensin-II 
(U-II),  A  disintegrin and metalloproteinase domain 12 (ADAM12), Prostaglandin F2α 
 (PGF2α) and Hyaluronan. 
 
Key messages 
1) Synovial fibrosis, which cannot be cured yet, contributes to joint pain and  stiffness 
in OA.
2) TGFβ signaling is on top of the fibrotic cascade in OA-related synovial fibrosis. 
3) PLOD2 is an interesting target to block to interfere with synovial fibrosis in OA.
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Introduction 
Fibrosis is a non-physiological wound healing process characterized by excessive  extracellular 
matrix deposition which is typically the result of inflammation or tissue damage. The 
 accumulation of excess fibrous connective tissue leads to loss of tissue  homeostasis and organ 
failure. Fibrosis is caused by a misbalance between extracellular matrix (ECM) synthesis and 
degradation and can occur in many tissues within the body including the synovium. 
When synovial tissue is affected by fibrosis, which is often the case in OA, it  becomes 
 thicker and more rigid (1). Synovial fibrosis contributes to joint pain and stiffness which are 
the main symptoms of OA (2-4). The underlying mechanisms which cause OA are still not 
 totally unraveled and, apart from joint replacement, no cure is available. This is an unmet 
need because OA is the most common joint disease and one of most  important causes of 
disability in the elderly (5). 
In the past, OA was considered a disease of the cartilage only. Nowadays, OA is  recognized 
as a whole joint disease, not only involving the cartilage, but also the  subchondral bone, 
 ligaments, meniscus and the synovium. Understanding how  synovial fibrosis contributes to 
OA pathology and symptoms might provide avenues for  future OA therapies. In this review 
we focus on processes/factors shown to play a role in OA-related synovial fibrosis. This will 
aid in choosing the best targets to interfere with OA-related fibrosis in future studies.
Synovial fibrosis in OA
The synovium
The synovium can be distinguished in two different layers (which are not clearly  separated 
by a membrane), the intima (synovial lining) which is 1-3 cell layers thick and subintima 
(sublining) which is up to 5 mm in thickness (in humans) (6). The  intima forms an interface 
between the cavity containing synovial fluid and the subintimal  layer. The subintima is com-
posed of loose connective tissue and merges with the dense  collagen-rich fibrous outer layer 
of the joint capsule. 
Based on the structure of the subintimal layer, the synovium can be divided in three main 
types of synovium 1) areolar synovium, 2) fibrous synovium and 3) adipose  synovium. Areolar 
synovium is composed of loose connective tissue and is often  crimped in folds. It is highly 
cellular and has a rich vasculature. Fibrous synovium  consist of a dense collagen  matrix, that 
is poorly vascularized containing less synovial lining cells/synoviocytes compared to areolar 
synovium. Adipose synovium has a single layer of synovial lining cells and contains a high 
quantity of mature fat cells. (6)
The synovium produces synovial fluid, which is crucial for chondrocyte nutrition, and 
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protects the cartilage from wear and tear by lubrication. To maintain a healthy fluid, a healthy 
synovium is required and is therefore crucial for normal joint movement/ function (6). 
Synovial abnormalities in OA
Multiple studies have shown that the synovium of patients, suffering from early or  advanced 
OA, have some form of pathology (7-10). Synovial pathology may impair joint functionality 
and contribute to disease progression by e.g. increased joint  friction (7). Oehler et al.  divided 
 osteoarthritic synoviopathy in four different subtypes based on different  characteristics 
of the synovium; hyperplastic, inflammatory, fibrotic and detritus -rich (9).  Hyperplastic 
 synoviopathy subtype is only present in early stage OA whereas the inflammatory  synoviopathy 
is found in both early and late stage OA. Fibrotic and detritus-rich syno viopathy were only 
observed in late stage OA.  Whereas no fibrosis was present in the hyperplastic subgroup and 
only to a minor extent in the  inflammatory subgroup, fibrosis was abundantly present in both 
the fibrotic and detritus -rich  synoviopathy. The main difference between the  inflammatory, 
 fibrotic and detritus-rich subgroup is that the inflammatory subgroup has less fibrosis but 
more lymphoplasmacellular infiltrate compared to the other two groups. Furthermore, 
the detritus-rich group differentiates itself by more fibrinous exudate and the presence of 
 cartilage and bone debris. Instead of fibrotic and detritus-rich  synoviopathy, we will use the 
more  general term synovial fibrosis for both synoviopaties in the rest of the article. Although, 
dividing synoviopathy in different subtypes may help grouping OA-patients and/or disease 
progression, we have to keep in mind that the observation of synovial fibrosis, at different time 
points, is patient- and site-dependent. Moreover, in most cases inflammation and  fibrosis can 
co-exist and are inter-dependent.
Kerna et al. reported enhanced level of inflammation, lining layer thickness, number of 
CD4+ T cells and macrophage infiltration in patients with very early OA compared to late 
stage OA (11). This confirms the observation by Oehler et al. that in early OA more inflam-
mation was present where in late stage OA more fibrosis was observed (9). These outcomes 
also support the study of Haraoui et al. that reported that the amount of  fibrosis is inversely 
proportional with the extent of cellular infiltrate in OA synovium, and the observation that 
fibrosis is mainly but not exclusively found in late stage OA. These results indicate a shift from 
inflammatory to the fibrotic subgroup which may suggest that the factors inducing fibrosis are 
upregulated in the inflammatory phase (8). 
Factors involved in synovial fibrosis
A vast number of factors can contribute to fibrosis, many of which are cell type/ disease 
 specific. Therefore, we performed a search for “synovial fibrosis osteoarthritis” via  pubmed 
limited for 2008 till 2015. This gave use 45 results and the following factors were reported to 
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be elevated in human with OA-related fibrosis (factors, only found to be  induced on mRNA 
level are omitted from the list): Transforming growth factor beta (TGFβ), procollagen- lysine, 
2-oxoglutarate 5-dioxygenase 2 (PLOD2) (also known as Lysyl hydroxylase 2b (LH2b)),  Tissue 
inhibitor of metalloproteinase 1 (TIMP-1), A  disintegrin and metalloproteinase  domain 12 
(ADAM12), Prostaglandin F2α  (PGF2α), urotensin-II and Mammalian target of rapamycin 
(mTOR) (12-17). From this list PLOD2, TIMP-1 and mTOR are also shown to be elevated in 
experimental OA  models (13, 17). Furthermore, lysophosphatidic acid is also found elevated 
in experimental  OA (18). 
Because we focus on the synovium, mTOR and lysophosphatidic acid were not  described 
in more detail, as these factors were only found elevated in chondrocytes/cartilage and not in 
synovial fibroblasts or the synovium. Connective Tissue Growth Factor (CTGF) was added 
to this list because this is a well-known fibrotic factor that also is shown to induce synovial 
fibrosis.
In addition, we selected from our search results also the factors that are shown to be 
 beneficial against fibrosis in an OA-like setting. Hyaluronan, polysulfated glyco saminoglycan 
(PS-GAG), parathyroid hormone PTH and Stanozolol were reported to be protective against 
OA-related fibrosis (Table 1) (19-23). We choose to describe hyaluronan in more detail 
 because this factor is found effective against OA-related fibrosis by multiple groups in  different 
 species, were the other factors are only described by one group and for one species. For all 
the selected factors more additional and background information was acquired via PubMed.
Table 1. Factors found to be protective against OA-related fibrosis
Factors found to be protective 
against OA-related fibrosis
Species Proposed/Possible mechanism 
to reduce fibrosis
Hyaluronan Ovine, horse, mice See chapter hyaluronan
Polysulfated 
glycosaminoglycan
Horse Decrease in inflammatory 
 mediators
parathyroid hormone Rabbits Inhibition of collagen, type 1, 
alpha 1
Stanozolol Ovine Reduced inflammatory phase
Transforming growth factor beta (TGFβ) signaling: central in the fibrotic cascade
TGFβ is the most well-known and best described fibrotic factor and a key player in many 
pro-fibrotic processes, including epithelial mesenchymal transition, enhancing  expression of 
TIMPs and elevating ECM deposition (24, 25). To our knowledge, TGFβ has been found 
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 involved/elevated in all fibrotic tissues researched so far, for  example (but not  exclusively): in 
fibrotic lesions of liver, lung, kidney, skin and heart tissue (26, 27). Furthermore, it has been 
shown in different fibrotic settings that inhibition of TGFβ signaling attenuates  fibrosis  whereas 
over expression of TGFβ causes fibrosis (26, 28, 29). Recently, it was shown that  blocking 
TGFβ can even diminish pre-existing fibrosis in a rat model of thioacetamide (TAA)-induced 
 hepatic fibrosis (30). Because, the liver might have a higher repair  capacity than the  synovium 
it is uncertain whether established synovial fibrosis can be reversed.  However, in other  model 
systems, it is shown that pulmonary fibrosis, cardiac and renal  fibrosis can be reversed, 
 making it plausible also synovial fibrosis is reversible (31, 32).  Furthermore, we showed in the 
past that CTGF-induced fibrosis is reversible overtime (33).
Ideally, to prevent fibrosis, one would like to block TGFβ, the top of the fibrotic  cascade. 
However, TGFβ is a regulator of many crucial cellular processes. Blocking TGFβ would result 
in serious side-effects and thus cannot be considered the ultimate cure for fibrosis.  Therefore, it 
is important to identify targets downstream of TGFβ that drive fibrosis to minimize  unwanted 
side effects. To identify these downstream targets of TGFβ for fibrosis therapy one should 
first understand how TGFβ signals in fibrosis. It is now common knowledge that TGFβ, by 
binding the TGFβ type II receptor, can signal via two distinct type one receptors, namely 
ALK5 and ALK1, which in turn phosphorylate receptor-Smads, Smad2/3 and Smad1/5/8, 
respectively (34). The receptor-Smads can form complexes with the common Smad (Smad4) 
and translocate to the nucleus to induce gene transcription. 
The role of ALK1 in fibrosis is not completely clear and literature on this seems to be 
 inconsistent. For instance, in irradiation-induced kidney fibrosis, ALK1+/− mice  developed 
less inflammation and fibrosis at 20 weeks after irradiation compared to wild type littermates 
(35). For scleroderma fibroblasts it was demonstrated that ALK5  dependent up regulation of 
collagen and connective tissue growth factor (CTGF), does not involve Smad2/3  activation 
but is mediated by ALK1/Smad1 and the TGFβ -induced non-Smad-dependent ERK1/2 
 pathways (36, 37). These observations indicate a pro -fibrotic role for ALK1. However, 
ALK1+/− mice with ureteral unilateral obstruction (UUO)-induced kidney fibrosis showed af-
ter 15 days  significantly higher expression of type I collagen compared to wild-type mice (38). 
 Furthermore, cultured renal fibroblasts from ALK1+/− mice expressed more collagen type I 
and fibronectin than fibroblasts derived from wild-type mice. These results  indicate a more 
anti-fibrotic role for ALK1, which is in contrast to the studies mentioned above.  Apparently 
within one organ, like kidney, the use of a different model system can result in a different out-
come. This  suggests that the role of ALK1 is not only cell type and tissue dependent, but also 
may influenced by the ailment of the tissue (39).
ALK5-mediated signaling is known to induce most of TGFβ’s pro-fibrotic effects and 
 inhibition of ALK5 have been shown to repress fibrosis in several fibrotic diseases (40-42). 
 Because ALK5 signals via both Smad2 and Smad3, which can potentially have different 
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 effects, their individual roles in fibrosis have been investigated, most frequently in epithelial 
cells. In these cells Smad3 acts pro-fibrotic whereas Smad2 protects against Smad3-mediated 
fibrosis (43-45). Because the specific roles of either smad2 or smad3 can be tissue-dependent 
the individual functions of Smad2 and Smad3 in the synovium have yet to be determined.
Besides the TGFβ-Smad pathways which are well described in general and  specifically 
regarding fibrosis, there are also Smad-independent TGFβ signaling pathways. The Smad- 
independent TAK-1 pathway is shown to have pro-fibrotic effects by regulating the  expression 
of extracellular matrix proteins, including collagens and  fibronectin (46). Furthermore, in a 
TGFβ-driven murine model of dermal fibrosis,  inhibition of  TGFβ-dependent ERK phos-
phorylation showed strong and dose-dependent anti- fibrotic effects on skin thickening 
(47). This indicates that not only the TGFβ-Smad pathways, but also the Smad-independent 
TGFβ signaling pathways have pro-fibrotic properties. Unfortunately, not much is known 
about these Smad-independent TGFβ signaling pathways concerning synovial fibrosis and 
their functions in the synovium, which puts limitations on selecting the optimal target to 
 interfere with synovial fibrosis. These non-Smad signaling factors are central mediators in 
multiple pathways, which makes their mechanism of action very elaborate and therefore they 
are  potentially less suitable as targets to interfere with synovial fibrosis.
Connective Tissue Growth Factor (CTGF), TGFβ’s right hand in the fibrotic cascade
CTGF is also known as CCN family protein 2 (CCN2). A primary function of CTGF is to 
 modulate and coordinate signaling responses involving cell surface proteoglycans, key 
 components of the extracellular matrix, and growth factors (48). During adulthood CTGF is 
expressed in endothelia and neurons in the cerebral cortex, where it  promotes  angiogenesis 
and tissue integrity, and in the female reproductive tract were it regulates both  follicle 
 development and ovulation (49-51). In addition CTGF is expressed in wound healing, 
 vascular diseases and fibrosis (52-54). 
CTGF is like TGFβ found to be elevated in many fibrotic diseases. There is no  unique 
receptor known for CTGF to which it binds with high affinity, and therefore CTGF is con-
sidered a matricellular protein that modulates the interaction of cells with the matrix which 
 modifies the cellular phenotype (55). It is suggested by Leask et al. that CTGF mediates its 
 effects through integrin- and heparin sulfate proteoglycan dependent  mechanisms and that 
the  ability of CTGF to bind cell surface heparin sulfate proteoglycans, which are highly  present 
in the joint, is essential for CTGF activity (56).
Because, no data is available about the interaction between TGFβ and CTGF in the  synovium, 
we will discuss “in our opinion” the best alternative, cellular signaling  responses in  fibroblasts 
in other tissues. As CTGF is a potent enhancer of fibroblast proliferation, chemotaxis, and 
 extracellular matrix (ECM) deposition, CTGF is thought to mediate some of TGFβ’s  fibrogenic 
effects after being upregulated by TGFβ (48, 57). Furthermore, CTGF  decreases Smad7, an 
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 inhibitory Smad which can inhibit TGFβ-signaling on multiple  levels, and via this  mechanism 
promoting TGFβ signaling (58). The mechanism by which CTGF regulates Smad7 is not yet 
fully unraveled. However, one proposed  mechanism in what way CTGF inhibits Smad7 is 
by induction of TIEG-1, which is upregulated via the TrkA signaling receptors for CTGF 
(59, 60). Depletion of CTGF in foreskin  fibroblasts with the use of adenoviral CTGF siRNA 
almost completely abrogated TGFβ-induced upregulation of collagen  synthesis, indicating 
CTGF not only enhances some of the pro-fibrotic effects of TGFβ but is also  obligatory for 
certain pro-fibrotic effects (61). 
Where others have demonstrated that only the combination of TGFβ and CTGF leads to 
persistent fibrosis, we have previously published that overexpression of TGFβ alone  causes 
persistent synovial fibrosis whereas CTGF alone in murine knee joint only causes transient 
 synovial fibrosis (28, 29, 33, 62). Because TGFβ is a potent  inducer of CTGF we cannot 
rule out the possibility that it is essential for the induction of  persistent  synovial fibrosis. 
It is  suggested by Wang et al. that the threshold level of CTGF  necessary to  induce persis-
tent  fibrosis may not be always reached by injecting TGFβ alone (29).  Therefore, a possible 
 explanation for this discrepancy might be that  overexpressing Ad-TGFβ results in higher 
 levels of TGFβ and subsequently higher CTGF levels  compared to protein  injection of TGFβ 
and therefore might reach the CTGF threshold required to induce persistent synovial fibrosis. 
In addition, both the synovial fibroblasts as well as the chondrocytes in the cartilage strongly 
induce CTGF  expression upon TGFβ stimulation (15, 63). Our finding that CTGF can cause 
transient  fibrosis is in line with the observations that CTGF by itself can promote collagen 
synthesis. However, one or more additional factors, elevated by TGFβ, seem to be required to 
induce persistent fibrosis (57, 64).
To validate CTGF as a potential anti-fibrotic target, it is important to  determine whether 
CTGF is necessary for the persistence of TGFβ-induced synovial fibrosis.  Especially  because 
a CTGF blocking antibody (FG-3019) is available. This antibody attenuated the fibrotic 
 response in three independent models of fibrosis, A model of multiorgan fibrosis induced 
by repeated intraperitoneal injections of CTGF and TGFβ, an unilateral ureteral obstruction 
(UUO) renal fibrosis model; and an intratracheal  bleomycin instillation model of pulmonary 
fibrosis (29).
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) 
PLOD2 is a collagen cross-linking enzyme, which activity induces the formation of-
pyrodinoline cross-links (65). Increased expression of Plod2 mRNA is found in  different 
fibrotic fibroblasts (66). Also the pyrodinoline cross-links, which make collagen fibrils less 
susceptible to enzymatic degradation and more rigid, are found to be  elevated in different 
fibrotic tissues (66). Diminished collagen degradation as a result of more  pyridinoline cross-
links per collagen triple helix, results in collagen accumulation, which is one of the hallmarks 
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of fibrosis. One of the most potent inducers of PLOD2 is TGFβ (15, 67). However, for skin 
fibroblasts it was shown that also IL-4, BMP-2, activin A and TNF-α can enhance PLOD2 
expression (67). For synovial fibroblast it was shown that besides TGFβ also prostaglandin 
f2α induces PLOD2 expression (14).
We observed in OA-induced fibrosis, that PLOD2 expression as well as a the  number of 
pyridinoline cross-links per collagen triple helix in the synovium were elevated (28). Most 
importantly, we also found elevated levels of PLOD2 in human end-stage OA  synovium (13). 
Because the presence of fibrosis in these OA patients was unknown, the average PLOD2  level 
might be even higher in the subpopulation of OA patients with fibrosis. This elevation sug-
gests that PLOD2 may be crucial in OA-related synovial fibrosis. At this moment, to our 
knowledge no blocking or overexpression studies of PLOD2 exist, to determine its direct 
function in the fibrotic process. However, based on the function of PLOD2 and the fact that 
it is highly induced in OA synovium, PLOD2 is an appealing target to interfere with synovial 
fibrosis.
Tissue inhibitor of metalloproteinase 1 TIMP-1
TIMP-1 is an inhibitor of the matrix metalloproteinases (MMPs), peptidases involved in 
 extracellular matrix degradation, and is found to be elevated in different fibrotic diseases e.g. 
pulmonary, liver and kidney fibrosis (68-70). We found that TIMP-1 is elevated in both the 
synovium of human end-stage OA patients and mice with experimental OA (13). TIMP1 is 
induced by TGFβ and is typically proposed as an enhancer of fibrosis  development but does 
not induce fibrosis itself (69, 70). Inhibition of TIMP-1 is  expected to result in higher MMP 
activity and therefore more ECM breakdown, which might be beneficial to diminish fibrosis. 
However, in unilateral urethral obstruction- induced  fibrosis there was no difference in the 
degree of interstitial fibrosis between wild- type and TIMP1-deficient mice (71). Most likely 
the role of TIMP-1 may vary  between  different types of fibrosis and its role in synovial fibrosis 
has yet to be  discovered.
Urotensin II (U-II)
Urotensin II is a potent vasoconstrictor which is involved in cardiac remodeling and may 
 influence cardiovascular homeostasis and pathology (72, 73). Furthermore, it may also 
 influence the central nervous system and endocrine function in man (73). In diff erent 
 fibrotic diseases, for example hepatic-, pulmonary- and cardiac fibrosis,  urotensin II  levels are 
 elevated (74-77). Moreover the authors of these articles suggest that  urotensin II is  involved 
in the development of fibrosis. Most fascinating, urotensin II levels were also reported to 
be  significantly higher in the synovial fluids of the osteoarthritis  patients compared to 
 control and may be associated with synovial fibrosis in osteoarthritis (16). It is reported that 
 urotensin II may  stimulate collagen synthesis via the ERK1/2 and TGFβ/Smad2/3 signaling 
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pathway and in this way contribute to fibrosis (72, 78). The exact signaling mechanism of 
urotensin II is however, largely unknown. Therefore more knowledge is needed about the 
 interplay  between urotensin II and TGFβ-signaling in synovial fibroblast and its potential 
role in  synovial fibrosis.
A disintegrin and metalloproteinase domain 12 (ADAM12)
ADAM12 is primarily involved in cell adhesion and fusion, extracellular matrix  restructuring, 
and cell signaling. There are two different splice variants, a shorter  secreted form (ADAM12-S) 
and a longer membrane-bound form (ADAM12-L) (79). Elevated serum levels of ADAM12-S 
are associated with elevated serum inflammatory markers, severity of skin fibrosis, and 
 increased activity of interstitial lung disease in diffuse  cutaneous systemic sclerosis,  suggesting 
a pro-fibrotic role for ADAM12 (80). Furthermore ADAM12-L was found to be elevated in 
the cartilage of OA patients (81). Most interestingly both ADAM12-S and ADAM12-L were 
upregulated in synovial  tissue of patients with OA and positively correlated with the grade of 
synovial fibrosis, suggesting a role for ADAM12 in OA-related synovial fibrosis (11, 81). 
ADAM12 is potently induced by TGFβ on both mRNA and protein level in  different cell 
 types including fibroblasts, enhancing epithelial to mesenchymal transition (EMT), a-SMA 
 expression and ECM production (82-84). The proposed mechanism by which ADAM12 
 induces its pro-fibrotic effects, is by positively regulating TGFβ signaling, due to the 
 stabilization of the TβRII protein (85). This stabilization might be accomplished by suppres-
sing the association of TβRII with Smad7, which prevents the receptor  complex degradation 
by Smad7 (85, 86). In line with these data, it was shown in hepatic  stellate cells that adding 
ADAM12 stimulates TGFβ-induced-phosphorylation of Smad2/3, whereas treatment of cells 
with antisense to ADAM12 diminishes the TGFβ–dependent induction of TGFβ-induced 
Smad2P (Smad3P was not measured in this study) as well as COL1A2 mRNA expression (86, 
87). ADAM12 can therefore be an important modulator of TGFβ-induced fibrosis.
Prostaglandin F2α (PGF2α)
PGF2α normally regulates a number of important physiological functions, like uterine 
 contraction and bronchoconstriction. However, elevated plasma concentrations of PGF2α 
metabolites found in idiopathic pulmonary fibrosis are significant associated with both  disease 
severity and prognosis (88). Oga et al. have shown that both PGF2α and TGFβ  increased 
the promoter activity of COL1A2, and simultaneous addition of both factors  synergistically 
 increased the COL1A2 promoter activity (89). Furthermore, prostaglandin F2α deficiency and 
inhibition of TGFβ signaling additively decrease fibrosis in mice with idiopathic  pulmonary 
fibrosis, suggesting that TGFβ and PGF2α recruit different signaling molecules to induce col-
lagen production (89). These results indicate that PGF2α has pro-fibrotic effects that works 
independently of TGFβ.
17
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The PGF2α isoforms 8-iso-PGF2α and 15-keto-dihydro-PGF2α were found significantly 
increased in the synovium fluid of patients with OA (90). Also relative high levels of PGF2α 
were measured in infrapatellar fat pad (from OA patients) conditioned medium (FCM) (14). 
Collagen production by fibroblast-like synoviocytes was positively associated with PGF2α 
levels in this FCM. In addition, gene expression of the collagen crosslinking gene, Plod2 was 
increased in fibroblast-like synoviocytes in the presence of this FCM. Inhibition of PGF2α 
levels reduced the extent of FCM-induced collagen production and Plod2 expression whereas 
inhibition of the TGFβ-ALK5 pathway with SB505124 did not alter the FCM-induced effects 
on fibroblast-like synoviocytes. These results indicate that elevated levels of PGF2α and it 
isoforms are present in an OA joint and that PGF2α has pro-fibrotic effects on the synovium 
that might differ from those induced by TGFβ.
Hyaluronan
Hyaluronan, is a glycosaminoglycan that bind the CD44 receptor. Injection of hyaluronan 
24 h after TGFβ injection in the TGFβ prior to treadmill running model of OA inhibited the 
cascade of OA-like joint changes including gait changes and synovial fibrosis.  Furthermore, 
hyaluronan injection post-surgery in the meniscectomy-induced OA model in sheep  reduced 
synovial fibrosis (23). These results show that hyaluronan protects against OA-related 
 fibrosis in both “intra-articular injection of TGFβ prior to treadmill running” model of OA 
and the meniscectomy-induced OA model in sheep (22, 23). This is in consensus with the 
 observation that exogenously provided hyaluronan antagonized TGFβ1-dependent myofi-
broblast differentiation (91). However, the exact mechanism how hyaluronan interferes with 
 synovial fibrosis is unknown. One suggested mechanism by Plaas et al., is that hyaluronan 
may act as anti-fibrotic by blocking ADAMTS5-mediated activation of profibrotic pathways 
in  periarticular cells (92). This, because hyaluronan can form a complex with Adamts5 and 
ablation of Adamts5 is shown to prevent both cartilage erosion and fibrotic remodeling in 
challenged joints (93). Another possible explanation is that interaction of hyaluronan with its 
receptor results in an increase in the association of the TGFβ receptor with Smad7, leading to 
TGFβ receptor degradation (85). This degradation leads to a decrease in TGFβ-signaling and 
 therefore in less fibrosis. That hyaluronan may be beneficial to reduce fibrosis by attenuating 
TGFβ-signaling, again suggests the major role of TGFβ signaling in fibrosis.
Targets to block synovial fibrosis in OA
The main cause of synovial fibrosis seems to be TGFβ-ALK5 signaling. Unfortunately,  blocking 
ALK5 may not be without any consequences for the cartilage. This because ALK5 is reported 
to promote type II collagen and aggrecan expression in chondrocytes (94, 95).  Additionally, 
TGFβ-Smad3 signaling, which is mediated via ALK5, suppresses MMP13 expression, and is 
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reported in multiple papers to repress chondrocyte hypertrophic differentiation and therefore 
OA (96-98). In contrast, there are also papers that propose that transition from an ALK5- 
mediated fibrogenic signaling to ALK1-mediated signaling in joint cells represents a transi-
tion from a nonreparative to a reparative chondrogenic cell phenotype (99). Taking all these 
results together indicate that inhibition of ALK5 comes with a certain risk for the cartilage 
and therefore better not can be inhibited in an OA-joint. Unless it is specifically blocked in the 
synovium to prevent fibrosis, which is unfortunately not yet possible. 
Whether inhibition of ALK1 in an OA joint has pro- or anti-fibrotic effects remains to 
be elucidated. This may be worth investigating because besides the potential anti-fibrotic 
 effects, inhibition of ALK1 is expected to reduce MMP13 expression in chondrocytes and 
therefore MMP mediated cartilage damage: a potential win-win situation (94, 95). However, 
to  minimize potential side effects, inhibition of a gene with as single or limited function has 
the preference over blocking genes with multiple function or that are at the top of an  extensive 
signaling pathway, such as TGFβ or PGF2α. In this regard the two most attractive options 
of the discussed factors are TIMP-1 and PLOD2 (Table 2). A major drawback of targeting 
TIMP1 in an OA joint is that elevated MMP activity will contribute to cartilage damage (100). 
Therefore inhibition of TIMP-1 in an OA-joint is not a preferred option to interfere with 
OA-related synovial fibrosis. PLOD2 on the other hand is a potential target to block in syno-
vial fibrosis. Noteworthy, cartilage containing high levels of pyridinoline collagen cross-links, 
which are increased due to PLOD2 activity, seems to fail mechanically in long term loading 
whereas areas containing low pyridinoline levels are less prone to degeneration (101). This 
suggests that inhibition of PLOD2, besides the potential anti-fibrotic effects may also favor 
cartilage repair in an OA joint. Unfortunately, there are no small molecular inhibitors availa-
ble yet to block PLOD2. Therefore alternative methods to target this intracellular enzyme 
in vivo, perhaps siRNA, have to be used. We look forward to an experiment were PLOD2 is 
blocked in an OA-model accompanied by fibrosis to determine whether this approach indeed 
prevent synovial fibrosis.
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Table 2. Pros and cons of inhibiting CTGF, PLOD2 or TIMP1 for the synovium and cartilage.
Expected effect on the synovium Expected effect on the cartilage
CTGF 
inhibition
Pro Less collagen synthesis. might 
attenuate the inflammatory 
cascade. (44, 52, 88)
Pro May prevent CTGF-mediated 
joint/cartilage destruction in 
OA. (21) 
Con unknown Con CTGF/CCN2 may play a role 
as an anti-aging factor by 
 stabilizing  articular cartilage. 
(21, 88, 89)
PLOD2
inhibition
Pro Less pyridinoline cross-links 
in the collagens triple-helixes. 
Prevents that the collagen 
 becomes harder to degrade 
and therefore prevents long 
lasting collagen accumulation. 
(16, 54, 55, 90)
Pro Cartilage areas containing low 
 pyridinoline levels are less 
 prone to degeneration com-
pared to cartilage containing 
high levels of pyridinoline col-
lagen cross-links which seems 
to fail mechanically by long 
term  loading. (86)
Con unknown Con unknown
TIMP1
inhibition
Pro More collagen degradation, as 
a result of more MMP activity 
may reverse the fibrosis. (91)
Pro unknown
Con unknown  Con More collagen degradation, 
due to more MMP activity. 
Causing more cartilage dama-
ge. (92, 93)
 
20
Discussion
Because it is estimated that over half of all OA patients suffer from synovial fibrosis it is 
 important that this pathological process receives more attention. Especially because fibrosis is 
one of the main causes of joint stiffness (2-4, 102). At present, there are no options to interfere 
with synovial fibrosis, however, preventing or reversing fibrosis in OA might result in major 
symptom relieve. The goal of this review was to provide an overview of the known factors 
that play a role in initiating and sustaining synovial fibrosis to facilitate selection of targets for 
anti-fibrotic therapies. 
Several factors can contribute to an excessive deposition of the ECM, which will result 
in synovial fibrosis by either increasing ECM synthesis or decreasing its degradation. The 
majority of these pro-fibrotic factors are downstream of TGFβ or modulate TGFβ signaling. 
There are other pathways that may contribute to synovial fibrosis independently of TGFβ, for 
instance PGF2α. It is hard to predict the relative contribution of those factors to the fibrotic 
process. Blocking studies will have to elucidate whether inhibition of one of these factors will 
break the fibrotic cascade in synovial fibrosis. 
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Outline of this thesis.
Besides cartilage damage and osteophyte formation, synovial fibrosis is one of the characte-
ristics of osteoarthritis (OA). More than 50% of the patients with end stage OA suffer from 
synovial fibrosis (chapter 1). This fibrosis greatly contributes to joint stiffness, one of the main 
symptoms of OA. 
In previous experiments, we found that overexpression of Transforming Growth Factor 
beta (TGFβ), a growth factor involved in a multitude of cellular functions, causes persistent 
 synovial fibrosis in murine knee joints, whereas Connective Tissue Growth Factor (CTGF) 
only induces transient fibrosis. Furthermore, inhibition of TGFβ prevents OA- related  fibrosis 
in murine experimental OA models. Because TGFβ-signaling has an important role in 
 cartilage maintenance and repair, simply blocking TGFβ in an OA joint may have adverse 
 effects and is for that reason not suitable to treat OA-related fibrosis. Therefore we searched 
for targets downstream of TGFβ to prevent OA-related fibrosis without interfering with 
joint homeostasis (chapter 2). The two genes, LH2b and TIMP1, which were the highest up-
regulated in different OA-related fibrotic conditions, were also examined on protein level on 
histology of murine knee joints with collagenase-induced OA. 
Because we were very intrigued by our earlier observation that showed that TGFβ caused 
persistent fibrosis whereas CTGF only induced transient fibrosis, we wanted to elucidate the 
origin of this difference (chapter 3). Therefore, we compared the expression of a number of 
genes thought to be relevant in fibrosis in synovium obtained from murine knee joints  exposed 
to either TGFβ or CTGF. Various extracellular matrix (ECM) components, ECM degrad-
ers, growth factors and collagen cross-linking-related genes were compared. The most pro-
nounced differences between persistent (TGFβ) and transient (CTGF) fibrosis was the high 
LH2b expression in the TGFβ-induced fibrosis group. LH2b activity results in the  formation 
of pyrodinoline cross-links, which make collagen harder to degrade and more  rigid, and is 
reported to be elevated in different fibrotic tissues. For that reason we investigated whether 
these pyridinoline cross-links were elevated in an experimental OA model accompanied by 
fibrosis and therefore, may influence the persistence of OA-related fibrosis. 
To test our hypothesis that these pyridinoline cross-links are responsible for the per-
sistence of synovial fibrosis we overexpressed CTGF combined with LH2b to examine wheth-
er this will make the CTGF-induced transient fibrosis persistent (chapter 4). Because LH2b 
appeared to be a highly attractive target to interfere with the fibrotic process, we wanted to 
elucidate via which signaling routes TGFβ activate LH2b (Chapter 5). Finally, we summarized 
the findings of this thesis and gave our final considerations (chapter 6). 
The general aim of this study was to elucidate the involvement of LH2b in OA-related 
synovial fibrosis.   
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Abstract
Objective. Synovial fibrosis is a major contributor to joint stiffness in osteoarthritis (OA). 
Transforming growth factor beta (TGFβ), which is elevated in OA, plays a key role in the 
onset and persistence of synovial fibrosis. However, blocking of TGFβ in OA as a therapeutic 
intervention for fibrosis is not an option since TGFβ is crucial for  cartilage maintenance and 
repair. Therefore, we undertook the present study to seek targets downstream of TGFβ for 
preventing OA-related fibrosis without interfering with joint homeostasis. 
Methods. Experiments were performed to deter- mine whether genes involved in  extracellular 
matrix turnover were responsive to TGFβ and were elevated in OA-related fibrosis. We 
 analyzed gene expression in TGFβ-stimulated human OA  synovial  fibroblasts and in the 
 synovium of mice with TGFβ-induced fibrosis, mice with  experimental OA, and humans 
with end-stage OA. Gene expression was determined by microarray, low- density array, or 
quantitative polymerase chain reaction analysis. 
Results. We observed an increase in expression of procollagen genes and genes encoding 
 collagen cross-linking enzymes under all of the OA-related fibrotic conditions  investi gated. 
Comparison of gene expression in TGFβ-stimulated human OA synovial  fibroblasts, 
 synovium from mice with experimental OA, and synovium from humans with end-stage OA 
revealed that the genes PLOD2, LOX, COL1A1, COL5A1, and TIMP1 were upregulated in all 
of these conditions. Additionally, we confirmed that these genes were upregulated by TGFβ 
in vivo in mice with TGFβ-induced synovial fibrosis. 
Conclusion. Most of the upregulated genes identified in this study would be poor targets 
for therapy development, due to their crucial functions in the joint. However, the highly 
up regulated gene PLOD2, responsible for the formation of collagen cross links that make 
 collagen less susceptible to enzymatic degradation, is an attractive and  promising target for 
interference in OA-related synovial fibrosis.
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Intoduction
Synovial fibrosis, characterized by fibroblast proliferation and an imbalance between col-
lagen synthesis and collagen degradation, is a hallmark of osteoarthritis (OA) (1). This im-
balance results in excessive deposition of collagen into the extracellular matrix (ECM) leading 
to  thickening and stiffening of the synovial membrane, which is believed to be a major 
 contributor to both joint pain and joint stiffness (2, 3). A key event in the onset of fibrosis is 
the response of fibroblasts to transforming growth factor beta (TGFβ) (4). TGFβ levels have 
been found to be elevated in the synovial fluid of OA patients (5–7); since large amounts 
of TGFβ are stored in cartilage, its elevated concentrations in the synovial fluid could be 
the  result of OA- related cartilage damage (8). We have previously demonstrated that intra 
 articular injection of adenoviral TGFβ into murine knee joints results in persistent synovial 
fibrosis and, more  importantly, that blocking of TGFβ in experimental OA strongly reduces 
synovial  fibrosis (9–11). These findings implicate TGFβ as the driving force in OA-related 
fibrosis. 
However, inhibition of TGFβ locally in the joints to prevent fibrosis in OA is not a feasible 
treatment option because TGFβ has an essential role in cartilage homeostasis (12): TGFβ and 
Smad2/3 signaling gives rise to the main cartilage components  aggrecan and type II collagen 
and suppresses matrix metalloproteinase 13 (MMP-13) (13). To  overcome this problem we 
sought to identify genes downstream of TGFβ that are  elevated in OA-related synovial fibrosis 
and therefore could be potential targets for  antifibrotic therapy in OA. We selected genes that 
encode for collagens, collagen- modifying  enzymes, proteinases, and collagen receptors (Table 
1). The proteins/ enzymes encoded by these genes affect collagen synthesis and degradation 
at different levels and could therefore influence the onset and progression of fibrosis. For 
example, collagen crosslinking enzymes, which are necessary for formation of stable fibrils, 
affect the susceptibility of collagen molecules to MMP activity. A collagen network with a 
high amount of  pyridinoline crosslinks is less susceptible to degradation by MMPs, which 
may lead to collagen accumulation and eventually fibrosis (14). In addition, reduced MMP 
activity or  increased expression of tissue inhibitor of metalloproteinases (TIMP) could be an 
alternative cause of collagen accumulation. 
In the present study, complementary DNA (cDNA) obtained from a variety of  sources 
was investigated in order to elucidate which of the above-described genes were upregulated 
by TGFβ and/or elevated in OA. Specifically, our studies were performed using cDNA from 
TGFβ-stimulated human OA synovial fibroblasts, synovium from mice with experimental 
OA or TGFβ-induced fibrosis, and most importantly, synovium from the affected joints of 
humans with end-stage OA.
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Table 1. All extracellular matrix turnover–related genes measured in transforming growth factor beta–
stimulated fibroblasts from patients with osteoarthritis (OA), synovium from patients with end-stage 
OA, and synovium from mice with collagenase-induced OA.
Gene category,                              
protein or enzyme encoded
Gene name Gene category,                              
protein or enzyme encoded
Gene name
Collagen-modifying enzymes Collagens
Lysyl hydroxylase 1 PLOD1 Collagen type I  1 chain COL1A1
Lysyl hydroxylase 2 PLOD2 Collagen type I  2 chain COL1A2
Lysyl hydroxylase 3 PLOD3 Collagen type III  1 chain COL3A1
Prolyl 4-hydroxylase 1 P4HA1 Collagen type IV  1 chain COL4A1
Prolyl 4-hydroxylase 2 P4HA2 Collagen type V  1 chain COL5A1
Prolyl 4-hydroxylase 3 P4HA3 Proteinases
Protein disulfide isomerase P4HB Collagenase 1 MMP1
Prolyl 3-hydroxylase 1 LEPRE1 Collagenase 2 MMP8
Prolyl 3-hydroxylase 2 LEPREL1 Collagenase 3 MMP13
Prolyl 3-hydroxylase 3 LEPREL2 Membrane type 1 matrix metal-
loproteinase
MMP14
Lysyl oxidase LOX Tissue inhibitor of metallo-
proteinases 1
TIMP1
Lysyl oxidase–like 1 LOXL1 Cathepsin K CTSK
Lysyl oxidase–like 2 LOXL2 ADAMTS-1, 2 ADAMTS2
Lysyl oxidase–like 3 LOXL3 ADAMTS-1, 3 ADAMTS3
Lysyl oxidase–like 4 LOXL4 ADAMTS-1, 14 ADAMTS14
Heat-shock protein 47 SERPINH1 Bone morphogenetic protein 1 BMP1
Procollagen C-endopeptidase 
enhancer
PCOLCE Collagen receptors
Procollagen C-endopeptidase 
enhancer 2
PCOLCE2 Discoidin domain receptor 
family, member 1
DDR1
Meprin A, alpha MEP1A Discoidin domain receptor 
family, member 2
DDR2
Meprin A, beta MEP1B Endocytic receptor 180 MRC2
Glycosyltransferase 25 domain–
containing 1
GLT25D1
Glycosyltransferase 25 domain–
containing 2
GLT25D2
FK506 binding protein 10, 65 kd FKBP10
Solute carrier family 39 member 
13
SLC39A13
Cartilage-associated protein CRTAP
Peptidylprolyl isomerase B PPIB
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Materials and methods
Human OA synovial fibroblasts. 
To examine which ECM turnover–related genes were responsive to TGFβ, we isolated human 
OA fibroblasts. Human synovium was obtained, with written informed consent, from 8 OA 
patients at the time of knee arthroplasty. The synovium was cut into samples of 3 mm3, and 
the samples were placed in a 6-well plate (3 samples/well). Fibroblasts were allowed to grow 
out of the tissue and to proliferate for 4 weeks, after which they were transferred to a culture 
flask and cultured for a maximum of 10 passages in  monolayer in BME medium (Gibco 
 Invitrogen) enriched with 10% fetal calf serum (Thermo Scientific HyClone), 50 g/ml 
 gentamicin (Centrafarm), and 1 mM sodium  pyruvate (Gibco Invitrogen) (15). The  fibroblasts 
were then cultured in a 24-well plate (Greiner Bio-One, CellStar) in serum-free medium for 
24 hours and  subsequently  stimulated with 10 ng TGFβ 1 (BioLegend) in serum-free medium 
for a further 24 hours. At the end of the  experiment the cells were harvested in 0.5 ml Tri 
Reagent  (Sigma). Gene expression levels in the TGFβ-stimulated fibroblasts were compared 
to those in unstimulated controls. 
Animals. 
Twelve-week-old male C57BL/6J mice were used for animal studies. The mice were kept in 
 filtertop cages with wood chip bedding. They were fed a standard diet with tap water  adlibitum. 
All animal experiments were approved by the Radboud University Nijmegen Medical Centre 
Committee on Animal Research and Ethics.
Collagenase-induced OA. 
Experimental OA was induced in mice by intra articular injection, on day 0 and day 2, of 1 unit 
of bacterial collagenase (Sigma) in a total volume of 6 μl 0.9% NaCl. The injection of  bacterial 
collagenase leads to joint laxity and subsequent OA lesions (16). This model  represents an 
equivalent of human secondary OA resulting from joint instability. Mice were killed on day 7, 
21, or 42 (n = 8 per group) and synovial samples were obtained for RNA isolation. Synovium 
obtained from the contralateral uninjected knee joints was used as a control. 
Isolation of messenger RNA (mRNA) from human OA synovial fibroblasts. 
Human OA synovial fibroblasts harvested in Tri Reagent as described above were  incubated 
with 100 μl chloroform. After 3 minutes of incubation the suspensions were centrifuged at 
11,000 revolutions per minute for 15 minutes at 4°C. Supernatants (240 μl) were  obtained 
and mixed with 240 μl isopropanol. This mixture was incubated for 10 minutes at room 
 temperature and subsequently centrifuged at 11,000 rpm for 10  minutes at 4°C. The RNA 
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pellets obtained were washed twice with 75% ethanol, dried, and dissolved in 8 μl RNase-free 
water (Fresenius Kabi). To remove chromosomal DNA contamination in the isolated mRNA 
samples, the samples were treated with DNase I (Invitrogen). 
Isolation of mRNA from murine and human synovial tissue. 
RNA isolation from murine or human synovium was performed with an RNeasy Mini kit 
(Qiagen). Synovial tissue samples were placed in RLT buffer (provided in the kit) in MagNA 
Lyser Green Beads tubes (Roche) and disrupted in the MagNA Lyser for 4 cycles of 20 seconds 
at 6,500 rpm with 1 minute of cooling on ice between cycles. The  remainder of the isolation 
procedure was performed according to the protocol  recommended by the manufacturer. 
Reverse transcription–polymerase chain reaction (RT- PCR). 
Isolated mRNA was transcribed into cDNA before being used for quantitative PCR (qPCR) or 
low-density array analysis. Eleven microliters (1 μg) of mRNA was mixed with 9 μl RT-PCR 
mix (1.9 μl distilled water, 2.4 μl 10× DNase buffer, 2.0 μl 0.1M  dithiothreitol, 0.8 μl dNTPs 
[each at 12.5M], 0.4 μl oligo[dT] primer [0.5 μg/ μl], 1.0 μl reverse transcriptase [200 μg/μl; 
Invitrogen], and 0.5 μl RNasin [Promega]). The RT-PCR protocol was as follows: 5 minutes 
at 25°C, followed by 60 minutes at 39°C and a final step of 5 minutes at 94°C. After the RT-
PCR procedure, the cDNA was diluted 20 times for further use in low-density array or qPCR 
analysis. 
Low-density array analysis. 
For each sample studied by low-density array analysis, 300 ng cDNA was loaded onto a 
custom-made 384-well TaqMan plate and run on a ViaA7 Real-time PCR system  (Applied 
Biosystems). Expression levels of the genes of interest were corrected for  GAPDH levels and 
for levels in control samples, and relative mRNA levels (2ΔΔCt) were calculated. 
Microarray analysis of murine synovium. 
Synovial samples obtained from the mice with collagenase-induced OA were analyzed using 
Affymetrix GeneChip Genome 430 2.0 arrays. Three arrays of pooled synovia from 2 mice 
were used at each time point. For microarray analysis of both human and murine synovial 
tissue, the quality of RNA was assessed using an Agilent Bioanalyzer. RNA (1 μg) was labeled 
and hybridization was performed according to the  Affymetrix  Expression Analysis Technical 
Manual for 1-cycle amplification. Array data were  analyzed using GeneChip operating soft-
ware (version 1.4) and Partek Genomics Suite software. 
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Microarray analysis of human OA synovium. 
To examine which of the selected ECM-related turnover genes were elevated in  human OA, 
synovial tissue samples were obtained, with written informed consent, from 7 OA patients 
at the time of arthroplasty. Synovial biopsy specimens obtained during an arthroscopic 
 procedure in 5 patients with suspected acute trauma of the knee joint were used as control 
samples. Human samples were analyzed using Affymetrix GeneChip Human Genome U133 
Plus 2.0 arrays. 
Quantitative PCR.
For qPCR, a primer mix consisting of 1 μl (2.5 μM) forward and reverse primer (see Supple-
mentary Table 1, on the Arthritis & Rheumatology web site at http://online library.wiley.com/
doi/10.1002/art.38266/abstract) was added to 5 μl SYBR Green  Master Mix (Applied 
 Biosystems). Next cDNA (3 μl) was added and the qPCR was run on a StepOnePlus  Real-Time 
PCR System according to the instructions of the manufacturer (Applied Biosystems). Relative 
mRNA levels (2ΔΔCt) were calculated by correcting the genes of interest for GAPDH levels and 
levels in control samples. 
Induction of fibrosis by TGFβ overexpression. 
To induce fibrosis, the right knees were injected intraarticularly with 1 × 107 plaque- forming 
units of an adenovirus overexpressing active porcine TGFβ 1 (Ad-TGFβ 223/225) in 6 μl 0.9% 
NaCl (Fresenius Kabi). Ad-luciferase was used as a viral control. The mice were killed on day 
7 after injection for histologic analysis or on day 21 after injection for gene expression analysis 
(n = 5 per group). Synovial biopsy specimens from individual mice were obtained for RNA 
isolation. 
Histologic and immunohistochemistry analyses. 
Mouse knee joints were processed and immunohistochemically stained as  previously  described 
(17). Specific primary antibodies against lysyl hydroxylase 2 (LH-2) (1:150;  Proteintech) or 
TIMP-1 (R&D Systems) were incubated overnight at 4°C. Incubation with  secondary  antibody 
(biotinylated goat anti-rabbit IgG or rabbit anti-goat IgG [both from  Vector]) was performed 
for 1 hour. A biotin–streptavidin detection system was used  according to the instructions 
of the manufacturer (Vector). Sections were counterstained with hematoxylin and mounted 
with Permount. 
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Statistical analysis. 
Statistical analysis of the low-density array and qPCR data was performed with SPSS 18.0. 
All low-density array and qPCR data were first checked for normality, by  Shapiro-Wilk test. 
Student’s paired t-test was used to assess the significance of  differences between groups in 
the human OA synovial fibroblast experiments. To assess the significance of differences 
 between groups in the TGFβ-induced fibrosis experiments, an independent sample t-test was 
 performed. The significance of differences between  non-normally  distributed groups was 
 determined by Wilcoxon’s signed rank test. Analysis of  variance with step-up false discovery 
rate correction for multiple testing (Benjamini and  Hochberg method) was used to determine 
the significance of microarray results. P values less than 0.05 were considered significant.
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Results 
Induction by TGFβ of genes encoding for collagen and crosslinking enzymes in  human 
OA synovial fibroblasts. 
Expression levels of ECM turnover–related genes were measured in  TGFβ-stimulated human 
OA synovial fibroblasts on a low-density array, to determine which of the  selected genes were 
downstream of TGFβ. We found increases in expression of the  collagen  genes COL1A1 (4.6-
fold), COL3A1 (2.5-fold), COL4A1 (4.8- fold), and  COL5A1 (3.7-fold) (Table 2), indicative of 
increased collagen synthesis, which is characteristic of fibrosis. Moreover, expression of 
 several genes encoding for crosslinking enzymes was  elevated  after TGFβ stimulation, with 
PLOD2 exhibiting the highest increase (25.2-fold). The other genes encoding for crosslinking 
enzymes that were upregulated by TGFβ were LOX (4.5-fold), LOXL2 (3.7-fold), LOXL3 
(10.7-fold), and LOXL4 (3.9-fold).  Furthermore, levels of the collagen-modifying enzymes 
PLOD3, P4HB, and LEPRE1 were elevated (4.6-fold, 2.2-fold, and 2.6-fold, respectively). 
 These results show that  genes encoding for collagens and crosslinking enzymes are highly 
responsive to TGFβ in OA synovial fibroblasts, with the latter regulated at the highest 
 amplitude. 
Table 2. Results of low-density array studies of human OA fibroblasts stimulated with TGFβ*
ECM turnover-related gene Relative expression (95% CI) P
PLOD2 25.2 (8.5–74.9) 0.003
LOXL3 10.7 (3.2–35.6) 0.013
COL4A1 4.8 (1.0–22.1) 0.046
PLOD3 4.6 (1.4–9.5) 0.016
COL1A1 4.6 (2.9–7.1) <0.001
LOX 4.5 (3.6–5.7) <0.001
LOXL4 3.9 (1.7–8.9) 0.007
LOXL2 3.7 (2.2–6.2) 0.001
COL5A1 3.7 (1.1–12.0) 0.036
P4HA1 3.0 (0.9–10.1) 0.069
PLOD1 2.9 (1.3–6.7) 0.068
LEPRE1 2.6 (1.3–5.3) 0.019
COL3A1 2.5 (2.1-3.0) <0.001
MMP14 2.4 (0.5–11.4) 0.184
P4HB 2.2 (1.1–4.2) 0.017
TIMP1 2.2 (1.5–3.2) 0.002
PPIB 2.0 (1.5–2.5) 0.001
* Extracellular matrix turnover–related genes whose expression was increased >2-fold  after stimulation 
with transforming growth factor beta (TGFβ) are shown. OA = osteoarthritis; CI = confidence interval.
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Elevated levels of TGFβ-inducible ECM turnover–related genes in the synovium of mice 
with collagenase-induced OA. 
To investigate whether the TGFβ-responsive ECM genes identified in the experiments using 
fibroblasts were also upregulated in OA synovium, we performed microarray  analysis on 
cDNA from the synovium of mice with collagenase-induced OA.  Performing the experiments 
at several different time points enabled us to study the kinetics of the selected ECM genes 
during the progression of fibrosis. 
At each time point assessed (day 7, day 21, and day 42), expression levels of Col1a1,  Col1a2, 
Col3a1, Col4a1, and Col5a1 were all increased in the synovium of mice with  experimental 
OA compared to the levels in synovium obtained from contralateral joints at the same time 
(Table 3). In parallel with the findings in fibroblasts, Plod2 was the most highly up regulated 
crosslinking gene in the synovium of mice with collagenase-induced OA. Moreover, the 
cross linking genes Lox, Loxl1, Loxl2, and Loxl3 were upregulated at all 3 time points, indica-
ting elevation of many crosslinking enzymes. The results did not differ significantly between 
time points. Expression levels of most genes, with the  exception of Timp1, Plod2, P4ha3, and 
Loxl3, were highest on day 7, with levels of the latter 4 genes peaking at later time points. 
Overall, up regulation of genes encoding for collagen and crosslinking enzymes in this OA 
model was consistent with the results observed in TGFβ-stimulated OA fibroblasts, indicating 
 comparable TGFβ signaling regulatory mechanisms. 
 
Table 3. Results of microarray studies of synovium from mice with collagenase-induced OA*
Day 7 Day 21                      Day 42
Gene Fold 
change
P Fold 
change
P Fold 
change
P
Timp1 ‡ 15.3 ± 1.3 0.003 13.5 ± 1.3 0.004 19.0 ± 0.4 0.002
Plod2 ‡ 6.2 ± 1.2 0.014 8.3 ± 1.1 0.006 6.9 ± 0.2 0.011
Ctsk 9.2 ± 0.7 0.0003 6.5 ± 0.8 0.001 5.0 ± 0.2 0.003
Col3a1 ‡ 8.1 ± 0.7 0.0007 5.2 ± 0.6 0.004 4.4 ± 0.1 0.008
Col1a1 ‡ 6.7 ± 0.6 0.0004 4.6 ± 0.7 0.002 4.3 ± 0.1 0.003
Mmp14 ‡ 8.3 ± 0.7 0.0005 5.0 ± 0.7 0.0037 3.9 ± 0.2 0.011
Mrc2 4.8 ± 0.2 0.002 4.3 ± 0.2 0.003 3.0 ± 0.1 0.016
Fkbp10 6.4 ± 0.8 0.0011 5.7 ± 0.6 0.002 3.0 ± 0.4 0.029
Col5a1 ‡ 5.6 ± 0.9 0.002 4.2 ± 0.7 0.0085 2.7 ± 0.2 0.046
P4ha3 2.3 ± 0.6 0.061 2.7 ± 0.6 0.033 2.7 ± 0.3 0.030
Crtap 4.7 ± 0.6 0.0002 3.6 ± 0.4 0.001 2.5 ± 0.3 0.009
Col1a2 4.5 ± 0.5 0.00008 3.0 ± 0.4 0.001 2.5 ± 0.2 0.004
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Day 7 Day 21                      Day 42
Gene Fold 
change
P Fold 
change
P Fold 
change
P
Serpinh1 4.4 ± 0.7 0.001 3.3 ± 0.5 0.005 2.5 ± 0.2 0.023
Loxl3 ‡ 3.2 ± 0.8 0.016 3.3 ± 0.6 0.016 2.5 ± 0.2 0.051
Leprel2 4.3 ± 0.6 0.0028 3.8 ± 0.4 0.005 2.5 ± 0.3 0.040
Pcolce 5.3 ± 0.8 0.0002 3.7 ± 0.8 0.002 2.4 ± 0.2 0.019
Adamts2 4.0 ± 0.6 0.0012 3.5 ± 0.5 0.002 2.4 ± 0.2 0.023
Lox ‡ 5.5 ± 0.8 0.001 4.2 ± 0.6 0.0048 2.3 ± 0.4 0.067
Loxl1 4.9 ± 0.5 0.00009 3.3 ± 0.5 0.001 2.3 ± 0.2 0.011
Loxl2 ‡ 5.3 ± 0.8 0.0003 4.3 ± 0.9 0.001 2.1 ± 0.1 0.045
Ppib ‡ 3.1 ± 0.5 0.0013 2.7 ± 0.4 0.003 1.9 ± 0.1 0.035
Ddr2 2.4 ± 0.4 0.0013 2.0 ± 0.3 0.006 1.5 ± 0.2 0.090
Col4a1 ‡ 2.7 ± 0.3 0.00002 2.1 ± 0.2 0.0003 1.4 ± 0.2 0.028
* ECM turnover–related genes whose expression was increased >2-fold on day 7 are shown. Values are 
the mean ± SEM. See Table 2 for definitions.
‡ Also upregulated in TGFβ-stimulated human OA fibroblasts.
Elevated levels of genes encoding for both collagen and crosslinking enzymes in  human 
end-stage OA. 
To investigate whether the upregulated expression of genes identified in the above- described 
experiments reflects expression in human end-stage OA, we  performed  microarray analysis 
of ECM-related genes in human end-stage OA synovium.  Expression levels of both  COL1A1 
and COL5A1 were elevated in synovium from  patients with end-stage OA (6.7-fold and 
4.0-fold, respectively) (Table 4), suggesting that procollagen synthesis in synovium remains 
 elevated even at this phase of the disease. An even more noteworthy finding was that ex-
pression levels of P4HA2, P4HA3, P4HB, LOX, LOXL1, LEPRE1, LEPREL1, PLOD1, and 
PLOD2 were increased (2.0–3.8-fold) in end- stage OA synovium. We thus demonstrated 
upregulation of genes for both collagen and  collagen-modifying enzymes (including those 
involved in crosslinking), indicating that fibrosis is maintained and/or still progressing in 
human end-stage OA. 
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Table 4. Results of microarray studies of synovium from patients with end-stage OA*
Gene Fold change P
COL1A1 6.7 ± 2.3 0.036
PCOLCE 4.1 ± 0.9 0.007
COL5A1 4.0 ± 1.0 0.012
P4HA3 3.8 ± 1.8 0.142
TIMP1 3.3 ± 0.7 0.006
LOX 2.9 ± 0.9 0.070
MRC2 2.8 ± 0.5 0.007
GLT25D1 2.5 ± 0.3 <0.001
SLC39A13 2.5 ± 0.4 0.001
LEPRE1 2.4 ± 0.3 <0.001
LEPREL1 2.4 ± 0.7 0.067
LOXL1 2.4 ± 0.6 0.039
FKBP10 2.4 ± 0.2 <0.001
MMP1 2.4 ± 1.8 0.4652
CRTAP 2.3 ± 0.3 0.001
P4HA2 2.2 ± 0.4 0.011
ADAMTS2 2.2 ± 0.5 0.027
PLOD1 2.0 ± 0.4 0.051
PLOD2 2.0 ± 0.4 0.035
P4HB 2.0 ± 0.3 0.008
* ECM turnover–related genes whose expression was increased >2-fold are shown. Values are the mean 
± SEM. See Table 2 for definitions.
Elevated levels of PLOD2, LOX, COL1A1, COL5A1, and TIMP1 in all 3 OA-related 
 fibrotic conditions.
By combining the data from the above-described experiments, we were able to  determine 
which TGFβ-inducible genes were elevated in both experimental and human OA. We found 
that PLOD2, LOX, COL1A1, COL5A1, and TIMP1 were upregulated by 2-fold in all of the 
OA-related fibrotic conditions tested (Figure 1) and therefore are most  likely both downstream 
of TGFβ and elevated in OA. To validate the microarray data,  expression of PLOD2, LOX, 
COL1A1, COL5A1, and TIMP1 in both the human and the murine samples was measured 
by qPCR. These results confirmed that each of the genes was upregulated in the OA -related 
fibrotic conditions compared to controls (for PLOD2, 17-fold and 7-fold in humans and 
mice, respectively; for LOX, 15-fold and 2-fold,  respectively; for COL1A1, 24-fold and 7-fold, 
 respectively; for COL5A1, 17-fold and 5-fold, respectively; and for TIMP1, 19-fold and 23-
fold, respectively). 
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To further validate our findings, TGFβ was over-expressed with an adenovirus in murine 
knee joints to determine whether gene expression of PLOD2, LOX, COL1A1, COL5A1, and 
TIMP1 is actually regulated by this growth factor in vivo. Analysis by qPCR revealed that 
after TGFβ overexpression, expression levels of these genes in mouse knee joints were indeed 
significantly elevated in the synovium (P < 0.05), with  upregulation of 18-fold, 13-fold, 10-
fold, 9-fold, and 8-fold for Col1a1, Plod2, Timp1, Lox, and Col5a1, respectively. Furthermore, 
immunohistochemistry analysis of Timp1 and Plod2 confirmed that their protein levels were 
also elevated in mouse knees with TGFβ-induced fibrosis (Supplementary Figure 1, on the 
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.38266/
abstract). These results,  taken together with the upregulation of the genes in experimental and 
human end-stage OA and the fact that TGFβ is a major factor in fibrosis, strongly suggest that 
one or a combination of these genes plays a crucial role in OA-related fibrosis.
Figure 1. Venn diagram showing extracellular matrix turnover–related genes that were upregulated by 
>2-fold in one or more of the following: transforming growth factor beta (TGFβ)–stimulated human 
osteoarthritis (OA) synovial fibroblasts, synovium from mice with collagenase-induced OA, and syno-
vium from humans with end-stage OA.
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Discussion 
Elevated TGFβ levels are the main cause of synovial fibrosis in OA (9). Recently it was shown 
that inhibition of TGFβ activity in the subchondral bone attenuated the  degeneration of 
 articular cartilage (18); however, blocking of TGFβ in an OA-affected joint to interfere with 
fibrosis would have adverse effects on cartilage homeostasis and is  therefore not a feasible 
therapeutic option. In this study we sought ECM turnover– related genes that are downstream 
of TGFβ and regulated in OA-related synovial  fibrosis, that could potentially be used for anti-
fibrotic therapy in OA. We found that PLOD2, LOX, COL1A1, COL5A1, and TIMP1 were 
upregulated both in OA fibroblasts  stimulated with TGFβ and in mice with TGFβ-induced 
fibrosis, which indicates that these genes are downstream of TGFβ and potentially crucial for 
fibrosis. The same  genes were also elevated in collagenase-induced OA as well as in human 
end-stage OA. Since these ECM-related genes are downstream of TGFβ and elevated in both 
experimental and  human OA as well as in TGFβ-induced fibrosis, they might be interesting 
treatment targets for interference with OA-related synovial fibrosis (Figure 2). 
TIMP-1, which inhibits MMP activity, has been found to be elevated in various  fibrotic 
diseases such as pulmonary, liver, and kidney fibrosis (19–21), and was also  enhanced in the 
OA-like fibrotic conditions investigated in the present study. In rats with immune-mediated 
fibrosis serum TIMP-1 levels were shown to reflect the severity of liver fibrosis (22), whereas 
in the collagenase-induced OA model the gene  expression levels of TIMP1 did not reflect the 
severity of the fibrosis, with fibrosis being much more severe on day 21 compared to day 7, 
while TIMP1 gene expression was higher on day 7 (11, 16). This is comparable to  observations 
in rats with CCl4-induced fibrosis, in which TIMP1 levels also did not cor relate with  fibrosis 
severity (22). It is also possible that TIMP1 gene expression levels do not reflect TIMP-1 
protein levels. TIMP-1 is  typically considered to be an enhancer of fibrosis  development that 
does not induce fibrosis by itself (19,20). However, in unilateral urethral  obstruction–induced 
fibrosis there was no difference in the degree of interstitial fibrosis between wild-type and 
TIMP1- deficient mice (23). This observation was explained by the possibility that, due to 
other  proteinase inhibitors, the function of TIMP1 was compensated for or that inhibition of 
the  intrinsic MMP activity does not contribute to a profibrogenic event in the kidney (23). 
 Increased MMP activity due to diminished TIMP1 activity might be beneficial for reducing 
 fibrosis. 
A possible consequence of targeting TIMP1 in an OA joint is that this will lead to  elevated 
MMP activity, which contributes to cartilage damage (24). Interference with collagen  synthesis 
might therefore be a better option for interfering with fibrosis. 
The upregulation of COL1A1 we observed in the OA-related fibrotic conditions met our 
expectations since type I collagen is the main collagen found in fibrotic  diseases  (25, 26). 
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In contrast to COL1A1, the increase in COL5A1 gene expression was not  anticipated  since 
this is not a general phenomenon in fibrotic diseases (27), although, consistent with the 
up regulation of COL5A1 observed in our models, elevation of type V collagen has been 
 demonstrated in rats with CCl4-induced liver cirrhosis (28). It has been suggested that in 
CCl4-induced  liver cirrhosis, type V collagen not only functions to connect type IV collagen 
with type I collagen fibrils, but also protects the parenchyma against excess type I collagen 
deposition.  Furthermore, it has been reported that type V collagen is important in the deter-
mination of fibril structure and matrix organization (29). Thus inhibition of type V collagen 
may lead to a dysfunctional collagen network. This, and the potential role of type V collagen 
in  protecting against excess type I collagen deposition, makes COL5A1 a less attractive target 
than  COL1A1. Furthermore, in all of the conditions we studied, induction of COL1A1 was 
higher than that of COL5A1, supporting the notion that COL1A1 is the major collagen in 
fibrosis. 
There are currently no available data on the effect of blocking type 1A1 or type 5A1 
 collagen in synovial tissue. Neither type I collagen nor type V collagen has a crucial role in 
cartilage (30), and therefore it can be anticipated that these genes can be safely  blocked  locally 
in an OA joint without compromising cartilage integrity.
Tendons and ligaments are composed primarily of type I collagen, but it is unlikely that 
 inhibition of type I collagen synthesis locally would affect the tendons and  ligaments in the 
joint since collagen turnover is very low in these tissues (31, 32). Although  blocking of the 
synthesis of these collagens might have little effect in healthy tendons and  ligaments, it can, 
however, be expected that healing of damaged tendons and ligaments would be impaired. 
The genes for both lysyl oxidase and LH2b (LOX and PLOD2, respectively) were 
 upregulated in all OA-like fibrotic conditions tested in our study. It is known that the  degree 
and type of crosslinks influences the susceptibility of collagen to enzymatic  degradation 
(14, 33). Two crosslink routes are responsible for the formation of  collagen crosslinks: the 
 allysine and the hydroxyallysine routes (34, 35). In the allysine route LOX converts lysine 
 residues within the telopeptide into the aldehyde allysine (36). This is a  critical step in cross-
linking of collagen fibrils. In the hydroxyallysine route a  hydroxylysine  residue within the 
telopeptide is converted by LOX into the  aldehyde  hydroxyallysine. LH2b converts the lysine 
in the telopeptides into hydroxylysine,  thereby inducing the hydroxyallysine route. This route 
lead to an elevation in pyridinoline crosslinks that  results in greater resistance of collagen to 
 enzymatic degradation (14, 34, 37). Interestingly, both LH2b and pyridinolines are elevated 
in various fibrotic tissues and organs (34,38). In the present study, the combined elevation of 
LOX and PLOD2 in OA-related fibrotic conditions indicates elevated crosslinking, favoring 
the  hydroxyallysine route (38, 39). 
To our knowledge there are no published reports describing the effect of blocking of 
PLOD2 on fibrosis. However, PLOD2 might be an interesting target to block in the OA joint 
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because this would reduce pyridinoline crosslink formation in the  synovium. This would, 
in turn, result in type I collagen that is more prone to degradation by MMPs, and  therefore 
 synovial fibrosis might be prevented/diminished. Furthermore, cartilage with collagen 
 containing low hydroxylysine and pyridinoline levels might be less prone to mechanically 
induced  degeneration since collagen with high levels of lysyl  hydroxylation and pyridino-
line crosslinking seems to fail mechanically under conditions of long-term loading (40). 
 Therefore, inhibition of PLOD2 will most likely favor cartilage repair  attempts. In addition, 
blocking of PLOD2 would be a safer alternative than blocking of type I collagen synthesis 
with regard to tendon and ligament repair, as the former does not affect collagen synthesis 
and “normal” cross linking by LOX is not altered. The only potential drawback could be that 
missing/ reduced pyridinoline crosslinks might reduce the strength of repaired tendons or 
ligaments. 
Others have shown that inhibition of LOX with β-aminopropionitrile  significantly 
 improves the bone marrow fibrotic phenotype in a mouse model of myelo fibrosis (GATA-
1–low mice) (36). Moreover, in Yorkshire pigs, inhibition of LOX with  β-aminopropionitrile 
reduced chamber and myocardial stiffness by inhibiting collagen crosslinking compared to 
that in normal untreated pigs (41). Therefore, blocking of LOX may be considered a potential 
therapeutic target for interference with OA-related  fibrosis. 
Of the genes identified in the present study, we propose that PLOD2 is the most  suitable as 
a target for interfering with OA-related fibrosis without negatively affecting joint  homeostasis. 
Blocking of TIMP1 or COL5A1 in the OA joint is not advised due to the disadvantages 
 described above. With inhibition of PLOD2, as opposed to LOX, only the hydroxyallysine 
route is blocked, and normal collagen maturation is still  possible  since the allysine crosslink 
route remains intact (39). Furthermore, inhibition of LOX may lead to decreased crosslinking 
of type II collagen, resulting in less mature and  weaker collagen, which will hinder  cartilage 
repair (42). With regard to  COL1A1, we  assume that complete blocking would be difficult 
to achieve, and a possible dis advantage of partial blocking of COL1A1 synthesis would be 
that an even greater imbalance  between procollagen synthesis and crosslinking enzymes 
could result. When this is the case the collagen helixes produced will be highly crosslinked, 
 resulting in collagen that is even more resistant to degradation, which eventually also can lead 
to  collagen accumulation. 
We mainly measured gene expression levels, which is a limitation of this study given that 
gene expression does not always reflect levels of protein. Therefore, we  additionally  performed 
immunohistochemistry analysis for TIMP-1 and LH2b to confirm that the  elevated mRNA 
 levels actually translated into highly elevated protein expression.  Another limitation of this 
study is that the human control synovium was obtained from patients who, though not 
 diagnosed as having OA or rheumatoid arthritis, had  suspected acute trauma  requiring 
arthroscopy. These patients are likely not fully  representative of the healthy population. 
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 Furthermore, the OA patients were not subdivided into groups with and without fibrosis, 
which might have resulted in an underestimation of the  actual fibrotic genotype. Despite this 
potential underestimation, however, we still identified  genes that were significantly induced 
during OA compared to controls. We used 4  different conditions to reflect “OA fibrotic” and 
compared these conditions in order to investigate which genes were elevated in all condi-
tions. The genes identified are thus highly likely to be of importance in OA-related fibrosis. 
Given the current findings, one of our future goals is to create an inducible PLOD2-knockout 
mouse, in which PLOD2 could be knocked out before and during OA progression in order to 
study its effect on fibrosis. We postulate that blocking of PLOD2/LH2 during OA will prevent 
the formation of pyridinoline crosslinks and will therefore reduce long-term fibrosis. 
In conclusion, in the present study we identified 5 potential target genes for  therapeutic 
interference with synovial fibrosis. Of these 5 genes—COL1A1, COL5A1, PLOD2, LOX, and 
TIMP1—we postulate that PLOD2 is a promising target.  Previously we demonstrated that 
elevated PLOD2 expression levels result in more pyridinoline crosslinks per triple helix in 
experimental OA (11). Now we have shown that PLOD2 is upregulated not only in mouse 
models of OA-related fibrosis, but also in human end-stage OA.
Figure 2. 
Schematic diagram showing the 
hypothetical mechanism of onset 
and maintenance of osteoarthritis 
(OA)–related fibrosis. TGFβ trans-
forming growth factor ; TIMP-1 
tissue inhibitor of metalloprotei-
nases 1; MMP matrix metallopro-
teinase. 
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Abstract
Objective. Fibrosis is a major contributor to joint stiffness in osteoarthritis (OA). We 
 investigated several factors associated with the persistence of transforming growth factor beta 
(TGFβ)-induced fibrosis and whether these factors also play a role in OA-related fibrosis. 
Design. Mice were injected intra-articularly (i.a.) with an adenovirus encoding either TGFβ 
or connective tissue growth factor (CTGF). In addition, we induced OA by i.a. injection of 
bacterial collagenase into the right knee joint of C57BL/6 mice. mRNA was isolated from the 
synovium for Q-PCR analysis of the gene expression of various extracellular matrix (ECM) 
components, ECM degraders, growth factors and collagen cross-linking-related enzymes. 
Sections of murine knee joints injected with Ad-TGFβ or Ad-CTGF or from experimental 
OA were stained for lysyl hydroxylase 2 (LH2). The number of pyridinoline cross-links per 
triple helix collagen in synovium biopsies was determined with high-performance liquid 
chromatography (HPLC).
Results. Expression of collagen alpha-1(I) chain precursor (Col1a1), tissue inhibitor 
of  metallo proteinases 1 (TIMP1) and especially procollagen-lysine, 2-oxoglutarate 
 5-dioxygenase 2b (Plod2b) were highly upregulated by TGFβ but not by CTGF. Elevated 
 expression of Plod2b mRNA was associated with high lysyl hydroxylase 2 (LH2) protein 
 staining after TGFβ overexpression and in experimental OA. Furthermore, in experimental 
OA the number of hydroxy pyridinoline cross-links was significant increased compared to 
control knee joints.
Conclusions. Our data show that elevated LH2b expression is associated with the  persistent 
nature of TGFβ-induced fibrosis. Also in experimental OA, LH2b expression as well as the 
number of hydroxypyridinoline cross-link were significantly upregulated. We propose that 
LH2b, and the subsequent increase in pyridinoline cross-links, is responsible for the  persistent 
fibrosis in experimental OA. 
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Introduction
Important hallmarks of osteoarthritis (OA) are cartilage degeneration, osteophyte  formation 
and fibrosis, resulting in both joint pain and stiffness. Fibrosis is characterized by excess 
 connective tissue accumulation, which can occur in many organs and can lead to organ  failure 
(1,2). In OA, fibrosis is a major contributor to joint stiffening and is  involved in joint pain (3). 
Two main players in fibrotic diseases which are also elevated in OA are  transforming growth 
factor beta (TGFβ) and connective tissue growth factor (CTGF) (4,5). 
TGFβ controls cell proliferation, differentiation and fulfills different roles in  immunity and 
wound healing but also plays a role in fibrosis in different organs (6-12). We have  previously 
shown that TGFβ plays an important role in synovial fibrosis in experimental OA, as blocking 
TGFβ could prevent synovial fibrosis (13). However, blocking TGFβ in OA is not an option 
as it is crucial for cartilage maintenance and repair (14,15). Besides TGFβ, CTGF has been 
 proposed as a major player in fibrotic diseases. CTGF can be induced by TGFβ through a 
TGFβ response element, however it can also function independent of TGFβ (16-18).  During 
adulthood, CTGF is expressed in endothelia and neurons in the cerebral cortex where it 
 promotes angiogenesis and tissue integrity (19-22). When it is expressed in other tissues it is 
mostly associated with wound healing, vascular diseases and fibrosis (22). 
By injecting an adenovirus overexpressing CTGF in murine knee joint we  previously 
 showed that CTGF can induce synovial fibrosis (23). However, in contrast to TGFβ- induced 
synovial fibrosis, which is persistent, CTGF overexpression resulted in fibrosis that was 
 resorbed by day 28. Others have also found that adenoviral expression of TGFβ  induced 
 pronouncedly prolonged fibrosis, while adenoviral expression of CTGF induced only 
 transient fibrosis (10,24). This raised the question: What causes this difference between TGFβ 
and CTGF-induced fibrosis, and specifically which factor(s) are responsible for the persistent 
nature of TGFβ-induced fibrosis?
Fibrosis results from an imbalance between matrix synthesis and matrix degra dation. 
 Therefore, we assessed the effect of either TGFβ or CTGF overexpression on mRNA  expression 
levels of various matrix turnover related genes and whether these give an  indication of the 
 observed differences. Thereafter we examined whether these factor(s) play a role in OA- 
related fibrosis. 
Here we report that lysyl hydroxylase 2b is strongly induced in TGFβ-induced  persistent 
 fibrosis and not in CTGF-induced transient fibrosis. Lysyl hydroxylases are collagen  modifying 
and crosslinking enzymes that convert lysine into hydroxylysine, thereby leading to cross-
links that make collagen harder to degrade (25-29). Especially LH2b, which hydroxylases the 
telopeptides and so induces the formation of pyridinoline collagen cross-links, makes collagen 
harder to degrade. LH2b and the pyridinoline cross-links it induces were both  significantly 
elevated in OA-related fibrosis.
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Materials and methods
Animals.
Male C57Bl/6 mice aged 12 weeks were used. Animals were kept in filtertop cages with 
 woodchip bedding. They were fed a standard diet with tap water ad libitum. The local 
 committee on animal research and ethics has approved this study.
CTGF and TGFβ overexpression.
We injected murine knee joints intra-articularly (i.a.) with 1 x 10e7 pfu virus in the right 
knee joint, thereby transfecting the synovial lining with an adenovirus overexpressing  active 
 porcine TGFβ1 (Ad-TGFβ223/225) (gift from Dr. C.D. Richards) or human CTGF (Ad- 
CTGF) (FibroGen, Inc., South San Francisco, CA, USA). As a viral control Ad-luc was used. 
The mice were sacrificed on day 3, 7 and 21. Synovial biopsies from at least five individual 
mice per group, were taken from the right knee joint for RNA isolation and subsequently 
Q-PCR. The right knee joints of mice injected with Adluc were used as controls for TGFβ1 
and CTGF injected joints. This experiment was repeated and whole knee joints were isolated 
for histology (n = 6 per group). Since the adenoviruses overexpress either porcine TGFβ or 
human CTGF we could distinguish these from endogenous murine TGFβ and CTGF with 
specific primer sets.
Collagenase-induced OA.
To induce OA, five units of bacterial collagenase in a total volume of 6 ml were injected i.a. 
into the right knee joint as previously described (30). Mice were sacrificed on day 7, 21, and 
42 and synovial biopsies were taken for RNA isolation (n = 4 per group*). This experiment 
was repeated for pyridinoline cross-link measurement and synovial biopsies were taken at day 
2, 7, 21, and 42 (n = 12 per group*). Whole knee joints were isolated for histology (n = 10 per 
group*) (day 7, 28 and 42). The left non-injected knee joints served as controls. The  injection 
of bacterial collagenase leads to joint laxity and subsequent OA lesions resembling those 
 occurring naturally in old mice. This model represents an equivalent to human  secondary OA 
resulting from joint instability. *Each number represents an individual mouse.
Quantitative PCR (Q-PCR).
RNA was isolated from the synovial biopsies with an RNeasy Mini Kit (Qiagen Inc.,  Valencia, 
CA, USA) after which an reverse transcriptase PCR (RT-PCR) was performed. Q-PCR was 
performed on the StepOnePlus Real-Time PCR System (Applied Biosystems,  Darmstadt, 
 Germany) according to manufacturers protocol. The used primer sets are displayed in 
 Table 1. Ct values of the genes of interest were corrected for glyceraldehyde-3- phosphate 
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 dehydrogenase (Gapdh) and there corresponding controls (delta delta Ct (ΔΔCt)). Each 
 biological sample was measured once. 
Histology and immunohistochemistry.
The murine knee joints were processed and immunohistochemically stained as previously 
 described (14). Specific primary Abs against LH2 (1/100) (Proteintech Group Inc., Chicago, 
IL, USA) were incubated overnight at 4 °C. The second antibody biotinylated goat anti-rabbit 
IgG (Vector Laboratories) was incubated for 1 h. A biotinestreptavidin detection system was 
used according to the manufacturer’s protocol (Vector Laboratories). Sections were counter-
stained with hematoxylin and mounted with Permount. 
The presence of fibrosis was determined by the synovial thickening, due to the  accumulation 
of extracellular matrix and increase in fibroblasts (histology), and at the increase in collagen 
alpha-1(I) chain precursor (Col1a1) gene expression (Q-PCR).
Cross-link measurement.
Synovial tissue samples (n = 12) were hydrolyzed in an oven with 6 M HCl at 110 °C for 20 
h. After drying (Speed Vac) samples were dissolved in 100 ml internal standard. The amount 
of hydroxyproline (Hyp) and the cross-links lysyl pyridinoline (LP) and hydroxylysyl pyridi-
noline (HP) in these samples were determined by reversed-phase high-performance  liquid 
chromatography (HPLC) as described by Bank et al. (31). To calculate the amount of HP 
per  triple helix the amount of HP (pmol) in the sample was divided by the total amount of 
 collagen (=Hyp/300). Values are expressed as total amount of residues per collagen molecule, 
assuming 300 Hyp residues per triple helix.
Statistical analysis.
First all data were checked for normality with the Shapiroe-Wilk test. To determine  significant 
(P < 0.05) differences between groups that were normally distributed a One-Way ANOVA 
with Gamese Howell post hoc test for multiple comparison was performed. Significant (P< 
0.05) differences between groups that were not normally distributed were determined with 
the Wilcoxon Signed Ranks Test. The statistical analyses were performed with the statistical 
software package SPSS 18.0 (SPSS, Chicago, IL, USA).
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Table 1. Primers used for Q-PCR. Primers were accepted if the deviation from slope of the standard 
 curve was less than 0.3 compared to the slope of GAPDH standard curve and if the melting curve 
 showed only one product. Efficiencies (E) for all primer sets were determined using a standard curve of 
five serial cDNA dilutions in water in duplicate.
Gene R2 E Forward primer (5’ → 3’) Reverse primer (5’→ 3’)
Gapdh 0.997 2.05 GGCAAATTCAACGGCACA GTTAGTGGGGTCTCGCTCCTG
Col1a1 0.997 2.10 TGACTGGAAGAGCGGAGAGTACT CCTTGATGGCGTCCAGGTT
Mmp3 0.997 2.21 TGGAGCTGATGCATAAGCCC TGAAGCCACCAACATCAGGA
Mmp9 0.998 2.15 GGAACTCACACGACATCTTCCA GAAACTCACACGCCAGAAGAATTT
Mmp13 0.992 1.93 ACCTTGTGTTTGCAGAG-
CACTAACTT
CTTCAGGATTCCCGCAAGAGT
Adamts4 0.996 2.10 CACTGACTTCCTGGACAATGGTTAT GGAAAAGTCGTCGGTAGATGGA
Adamts5 0.994 1.97 GATGATCACGAAGAGCACTACGA TCACATGAATGATGCCCACAT
Timp1 0.972 1.93 CAACTCGGACCTGGTCATAAGG CATCTTGATCTTATAACGCTGGTA-
TAAGG
Tgf-β1 0.996 2.00 GCAGTGGCTGAACCAAGGA AAGAGCAGTGAGCGCTGAATC
Ctgf 0.998 2.15 CCGCCAACCGCAAGATC ACCGACCCACCGAAGACA
Plod1 0.997 1.90 GGAGCCGAACAGCCTAAGG TGAGTGGCGCAATGACATTC
Plod2 0.997 2.08 GAGCAGCCTTGTCCAGATGTC CCAACTCATCACAGGCTCGTT
Plod2b 0.999 1.93 CCGCAATGCTAGAGATATGACCTT CATTTGGAATGTTTCCGGAGTAG
Plod3 0.993 2.02 AAGACACGGGCAGTGATGAACT AAGCGAGGGCTGCTCATCT
Human 
CTGF
0.999 2.03 GCCCTCGCGGCTTACC AGGCAGTTGGCTCTAATCATAGTTG
Porcine 
Tgf-β1
0.997 1.99 TGACCTGGCCACCATTCAT TCCGTGGAGCTGAAGCAATA
Table 2. Ct values of human CTGF and porcine 
TGFβ. Mice were injected i.a. with an adeno-
virus encoding either TGFβ or CTGF or a control 
 virus. Three, 7 and 21 days after injection of the 
adenovirus synovial biopsy punches were taken 
of which RNA was isolated. Primers detecting 
only viral CTGF (human, not murine) and only 
viral TGFβ (porcine, not murine) were used to 
evaluate whether expression was sustained over 
a period of time. Ct values were corrected for 
 Gapdh. Higher Ct values thus represent a lower 
ression. Nd = not detectable. Clearly, viral CTGF 
was only found in synovial biopsy punches of mice injected with Ad-CTGF and viral TGFβ was only 
detected in synovial biopsy punches of mice injected with Ad-TGFβ. The expression levels declined in 
time, but expression was still clearly detectable at day 21
Sample Human 
CTGF
Porcine 
TGF-β
Control virus day 3 Nd Nd
Control virus day 7 Nd Nd
Control virus day 21 Nd Nd
Ad-TGF-β day 3 Nd 9.6
Ad-TGF-β day 7 Nd 11.2
Ad-TGF-β day 21 Nd 13.6
Ad-CTGF day 3 7 Nd
Ad-CTGF day 7 10.2 Nd
Ad-CTGF day 21 13.0 Nd
expression. Nd = not detectable. Clearly, viral CTGF was only found in synovial biopsy punches of mice
injected with Ad-CTGF and viral TGFβ was only detected in synovial biopsy punches of mice injected
wi h A -TGFβ. The ex ressio  levels declined in time, but expression was still clearly det table at
 day 21.
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Results
To address the question which factors could be responsible for difference in TGFβ- induced 
persistent and CTGF-induced transient fibrosis, we evaluated the expression of several 
 extracellular matrix components, matrix proteases, as well as growth factor expression and 
modulators of collagen cross-linking. First we checked whether the adenoviruses, which were 
intra-articular injected in the right murine knee joint, induced expression of human CTGF 
and porcine TGFβ. This showed clear expression of both factors until at least day 21 (Table 2). 
Ad-TGFβ induces both endogenous TGFβ and CTGF mRNA expression.
We examined the effect of adenoviral overexpression of CTGF or TGFβ on the endogenous 
expression of CTGF and TGFβ. Adenoviral overexpression of TGFβ induced relatively high 
levels of endogenous (murine) TGFβ1 and CTGF, with maximal induction levels of 3.5 ΔΔCt 
(P < 0.0001) for TGFβ1 at day 7 and 3.8 ΔΔCt (P < 0.0001) for CTGF on day 3 (Figure 1a). 
Adenoviral overexpression of CTGF only resulted in a small increase (1.3 ΔΔCt) of TGFβ on 
day 7. Further there were hardly any changes induced by Ad-CTGF with regard to the endo-
genous expression levels of CTGF and TGFβ (Figure 1b).
Figure 1. mRNA expression (ΔΔCt) of endogenous TGFβ and CTGF in murine synovial tissue. Mice 
were injected i.a. with an adenovirus encoding either TGFβ1 or CTGF. Three, 7 and 21 days after 
 injection of the adenovirus, synovial biopsy punches were taken of which RNA was isolated. ΔΔCt 
 values were calculated by correcting the Ct values of the genes of interest for GAPDH and there 
 cor responding  controls. [a] TGFβ induced elevated levels of TGFβ1 RNA. In addition, Ad-TGFβ over-
expression  resulted in elevation of CTGF RNA expression. [b] Ad-CTGF only resulted in a significant 
(P = 0.02) increase of TGFβ on day 7. The endogenous levels of CTGF were not affected by Ad-CTGF.
[A]                         Ad-TGFβ      [B]                      Ad-CTGF
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Elevated gene expression of Mmp3/9/13, Adamts4 and Timp1 by Ad-TGFβ
TGFβ induced the expression of most of the studied matrix metalloproteinases (MMPs), a 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) and tissue 
 inhibitor of metalloproteinases 1 (Timps). Expression of Mmp13 and Adamts4 were  strongly 
elevated on all measured days (Figure 2a). Timp1 expression was highly elevated by TGFβ 
overexpression with a maximum at day 7 of 5.8 ΔΔCt (P< 0.0004) compared to normal 
 expression. Compared to TGFβ, CTGF only significantly induced Adamts4 (1.9 ΔΔCt; P = 
0.0168),  further it did not significantly change any of the measured expression levels more 
than 1.5 ΔΔCt (Figure 2b).
Figure 2. mRNA expression (ΔΔCt) of various enzymes in the synovial tissue. Mice were injected i.a. 
with an adenovirus encoding either TGFβ or CTGF. Three, 7 and 21 days after injection of the adeno-
virus synovial biopsy punches were taken of which RNA was isolated. ΔΔCt values were calculated 
by correcting the Ct values of the genes of interest for GAPDH and for control samples. [a] Ad-TGFβ 
induced the highest changes on day 7, with most marked changes in expression of MMP3, MMP13, 
ADAMTS4 and TIMP1. [b] Overexpression of Ad-CTGF resulted in a significant induction of MMP3 
(P = 0.008) and ADAMTS4 (P = 0.017) at day 7. MMP9 was downregulated by Ad-CTGF at day 7 (P = 
0.003) and 21 (P = 0.011).
[A]                                                             Ad-TGFβ     
[B]                                                             Ad-CTGF
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Ad-TGFβ, but not Ad-CTGF, induces procollagen-lysine, 2-oxoglutarate 5-dioxygenase 
2b (Plod2b) mRNA expression in murine synovium.
Since, collagen cross-linking can have a major impact on the degradation of collagen we 
also evaluated the levels of mRNA expression of the lysyl hydroxylases (enzymes involved 
in  collagen cross-linking). The family of lysyl hydroxylases consists of: LH1, LH2 and LH3 
which are coded by Plod1, Plod2, and Plod3 respectively. LH2 has two alternative splice- 
variants: LH2a and LH2b. TGFb induced all Plods with the highest expression on day 7 
 (Figure 3a). Strikingly, TGFβ overexpression resulted in very high Plod2b expression le-
vels, with an induction of approximately 4 ΔΔCt (P < 0.003) on all measured days. Adeno-
viral over expression of TGFβ also resulted in elevated expression levels of Col1a1 mRNA in 
 synovium on all  measured days, with a maximum increase (4.7 ΔΔCt; P < 0.0001) on day 7 
compared to controls (Figure 3a). CTGF had no effect on Plod gene expression levels on day 
3 and day 7, at day 21 Plod2(b) and Plod3 were somewhat downregulated but this was not 
significant (Figure 3b). In contrast to TGFβ, and rather unexpected, CTGF did not induce the 
expression of Col1a1.
Figure 3. mRNA expression (ΔΔCt) of various lysyl hydroxylases and Col1a1 in the synovial tissue. Mice 
were injected i.a. with an adenovirus encoding either TGFβ or CTGF. At day 3, 7 and 21 after  injection of 
the adenovirus synovial biopsy punches were taken for RNA isolation. ΔΔCt values were calculated by 
correcting the Ct values of the genes of interest for GAPDH and for control samples. [a, b] In contrast 
to CTGF, TGFβ induced expression levels of all measured Plods. The most marked change was observed 
in Plod2(b) expression, which was strongly induced on all measured days. Col1a1  expression was also 
induced after Ad-TGFβ overexpression but not after Ad-CTGF overexpression.
[A]                                                       Ad-TGFβ     
[B]                                                       Ad-CTGF
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Ad-TGFβ-induces persistent fibrosis which is accompanied by elevated LH2 protein ex-
pression. 
Having found a particularly high Plod2(b) gene expression in the synovium, we investi gated 
if this translates into LH2 protein expression. To this end, we stained paraffin sections of the 
murine knee joint transduced with either CTGF or TGFβ for LH2. First we  investigated if 
the synovium was thickened. After TGFβ overexpression there was a strong increase in the 
 thickness of the synovium over time, which was still present on day 21 (Figure 4c). CTGF 
overexpression resulted in synovial fibrosis with a peak on day 7, which was completely 
 resolved on day 28 (Figure 4b). These results support our earlier published observations that 
over expressing TGFβ leads to persistent fibrosis whereas CTGF induces transient fibrosis. 
 Similar to LH2b mRNA expression after TGFβ overexpression, LH2 protein expression was 
the highest on day 21 (Figure 4c). However, on day 3 and 7 there was also a clear increase 
in LH2 protein expression compared to the control knee joints. As expected, CTGF did not 
influence LH2 protein expression (Figure 4b).
Figure 4. [a] Normal murine knee joint, with the area that is displayed in the histology figures. [b, c] 
Immunohistochemically staining for LH2 protein expression in the synovial tissue of murine knee joints 
after i.a. of CTGF or TGFβ. TGFβ overexpression resulted in a strong increase over time in the thickness 
of the synovial membrane starting at day 3. CTGF-induced fibrosis was most abundant at day 7 and 
was completely resorbed at day 28. In contrast to CTGF, overexpressing of TGFβ strongly induced LH2 
 expression in the synovium, especially at day 21 (Original magnification × 100).
[A] [B]  Ad-TGFβ --> transient fibrosis 
[C]  Ad-TGFβ --> persistent fibrosis
65
    
Chapter 3
Plod2b mRNA is elevated in collagenase-induced OA 
Because Plod2b was strongly upregulated in TGFβ-induced persistent fibrosis we inves tigated 
if Plod2b was also elevated in OA-related synovial fibrosis in collagenase-induced OA. We 
found that in collagenase-induced OA there was a significant and longlasting increase of 
Plod2b gene expression. The highest induction of 6.3 ΔΔCt (P< 0.0001) was measured on day 
7, however Plod2b was still significant increased on day 21 and 42 (Figure 5a). Thus, com-
parable to TGFβ-induced fibrosis, Plod2b gene expression is also elevated in experimental 
OA-related fibrosis.
LH2 protein expression is strongly induced in OA-related fibrosis.
Histological sections of murine knee joints were stained for LH2, to assess if LH2 protein 
 expression was induced in OA-related fibrosis. A clear increase in LH2 protein expression 
was observed in the synovium at all measured time points (Figure 5b). Especially on day 7 
there was a very strong increase in LH2 expression, while on both day 21 and 42 LH2 protein 
expression was still elevated but less intense than on day 7. The thickness of the synovium of 
the murine knee joints with collagenase-induced OA was mildly increased at day 7, while a 
large increase was seen on day 28 and 42. LH2 protein expression being strongly elevated in 
collagenase induced OA, indicating LH2(b) may play a key role in OA-related fibrosis.
Elevated number of HP cross-links in synovium in experimental OA.
To determine whether a higher LH2b expression level results in an increase of  pyridinoline 
cross-links, the number of LP and HP per triple helix was measured in the synovium of mice 
with collagenase-induced OA. The amount of LP was under the detection limit at all  measured 
time points. However, there was a significant increase in the number of HP cross-links per 
 triple helix on both day 21 and 42, with a 1.8-fold increase on day 21 and a 2.6-fold increase 
on day 42 compared to unaffected left control joints (Figure 5c). This indicates that elevated 
levels of LH2b expression during experimental OA indeed result in more pyridinoline cross-
links per triple helix. Suggesting the formation of more degradation-resistant collagen (27). 
Figure 5. 
[a] Plod2b mRNA expression (ΔΔCt) in the synovial 
tissue of murine knee joints with collagenase-induced 
OA. Plod2b mRNA expression was significantly in-
duced on all measured days in the synovium of OA- 
affected joint compared to the healthy control joints. 
This increase was with an induction of 6.3 ΔΔCt the 
strongest on day 7, but was still 1.6 ΔΔCt increased at 
[A]
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Figure 5. [b] Immunohistochemically staining for LH2 protein on murine knee joints with collagenase- 
induced OA (Original magnification × 100). The picture is focused at the synovial tissue lateral of the 
growth plate (see Figure 3a). At day 7 a mild increase in the thickness of the synovial membrane was 
seen whereas on day 28 and 42 a strong increase in synovial thickening was observed. LH2 expression 
was strongly induced in the synovium at day 7, on day 28 and 42 LH2 was still elevated but less intense 
compared to day 7. [c] HPLC cross-link measurement in synovial punches, obtained from mice with 
collagenase-induced OA (n = 12 per group). The number of pyridinoline crosslinks per triple helix was 
significantly elevated on day 21 and 42 in the synovium of murine knee joints with collagenase-induced 
OA compared to unaffected left control joints.
Naive   Day 7       Day 21             Day 42
[B] [C]                        HP per Triple Helix
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Discussion
Synovial fibrosis is thought to contribute significantly to joint stiffness (3). Previously we 
have shown that TGFβ induces persistent fibrosis whereas CTGF induces reversible  fibrosis 
(23,32,33). In this study we evaluated several factors to get an indication why TGFb  induces 
persistent fibrosis and CTGF induces only transient synovial fibrosis and whether the  factors 
are involved in the persistent nature of OA-related fibrosis. The most pronounced and 
 abundant induction we detected was the induction of LH2b by TGFβ. In addition, we found 
that LH2b gene expression and LH2 protein expression as well as the number of pyridinoline 
cross-links per triple helix were strongly induced in experimental OA. 
First we explored if the endogenous levels of TGFβ1, and CTGF were altered by over-
expressing either TGFβ or CTGF. Overexpression of TGFβ resulted in the induction of 
 endogenous TGFβ and CTGF, whereas overexpressing CTGF had no noteworthy effects on 
endogenous CTGF and TGFβ. TGFβ autoinduction could contribute to the potentiation of 
TGFβ induced effects. However, TGFβ-induced fibrosis persists for months whereas TGFβ 
autoinduction strongly diminished in time. Therefore it is unlikely that TGFβ autoinduction 
is the cause of the persistence of TGFβ induced fibrosis.
As expected, endogenous CTGF was induced by overexpressing TGFβ. In contrast to 
our finding, several other groups have established that fibrosis induced by TGFβ alone was 
not persistent and that only simultaneous application of CTGF and TGFβ resulted in long-
term fibrotic tissue formation in skin of mice (34-36). In our system, TGFβ was sufficient to 
 maintain fibrosis maybe supported by the induced CTGF. Our results show that Ad-CTGF 
overexpression, which induces high CTGF expression, gives mild and transient fibrosis. Since 
CTGF alone only induces transient fibrosis, CTGF is most likely not the factor responsible for 
the persistence of TGFβ-induced fibrosis.
Expression of Col1a1 mRNA levels was highly upregulated by TGFβ when compared to 
CTGF or controls. We expected Col1a1 upregulation by both TGFβ and CTGF, but we found 
almost no upregulation after Ad-CTGF exposure. This was unexpected as type 1 collagen is 
the major component of fibrosis and has frequently been found upregulated by CTGF (17, 24, 
37, 38). However, Bonniaud et al. found a 3-fold upregulation of Col1a1 mRNA at day 14 after 
Ad-CTGF exposure but they did find only a small increase (approximately 1.5-fold) in Col1a1 
mRNA expression on day 3 and 7 and approximately 0.75 at day 21 (24). Thus, we might have 
missed the window in which this increased expression could have been present. 
High type 1 collagen production maybe crucial in the building up process of fibrosis. 
 However type 1 collagen, without an elevation in the number of pyridinoline cross-links can 
be degraded by different enzymes and may therefore have a limited role in the  persistence 
of fibrosis. We expected that the reversibility observed in CTGF-induced fibrosis might 
68
be due to a higher degree of ECM degradation, but in fact TGFβ led to elevated levels of 
MMP  expression, whereas CTGF hardly influenced the expression of the proteases explored. 
TGFβ also induced elevated Timp1 expression, proteins that are able to inhibit MMPs and 
might prevent or reduce MMP-mediated matrix degradation. The outcome of the effect of 
Timp1 on TGFβ-induced synovial fibrosis is probably determined by the balance between 
the TIMPs and MMPs. The increase at day 21 in Mmp13 mRNA expression was higher than 
Timp1 mRNA expression, suggestive for Timp1 not being responsible for the persistence of 
 TGFβ- induced fibrosis. The net effect of this balance on matrix turnover however is hard to 
predict. 
Since the previous described genes did not clarify the persistent nature of  TGFβ-induced 
fibrosis, we also examined differences in collagen cross-linking enzymes. A prominent 
 observation was that TGFβ induced high expression of Plod2 in the synovium, especially 
Plod2b, whereas CTGF did not induce any significant changes in Plod mRNA expression 
levels. That TGFβ is able to induce Plod2/LH2b was earlier shown by van der Slot et al. in skin 
fibroblasts (25). They also showed that fibroblasts of several fibrotic disorders had  increased 
levels of Plod2/LH2b mRNA expression. Induced LH2b results in overhydroxylation of  lysine 
residues within collagen telopeptides which leads to increased formation of pyridinoline 
cross-links, making collagen harder to degrade by proteases (27, 39, 40). This could explain 
why the elevated Mmp13 and Adamts4 mRNA levels do not interfere with the persistence 
of TGFβ-induced fibrosis. This also might explain why CTGF-induced fibrosis is transient, 
whereas TGFβ-induced fibrosis lingers at least for months. 
We investigated if Plod2 is also involved in OA-related synovial fibrosis in collagenase- 
induced OA. In this OA model that is accompanied by fibrosis both Plod2b mRNA and LH2 
protein expression levels were strongly elevated. We postulated that the strong induction of 
LH2b in the beginning of collagenase-induced OA lead to overhydroxylation of lysyl groups 
in the telopeptides of procollagen molecules. During the maturation process these over-
hydroxylated procollagen molecules will form more pyridinoline cross-links per triple helix 
compared to not overhydroxylated procollagen. We measured the amount of pyridinoline 
cross-links per triple helix and as hypothesized these were significantly elevated on day 28 and 
42. This finding was not unexpected because collagen cross-link maturation may take several 
weeks (41). This increase in pyridinoline cross-links will result in collagen that is harder to 
degrade, and lead to persistent fibrosis after TGFβ exposure and in experimental OA. 
We have shown that LH2b gene expression and LH2 protein were induced in both 
 TGFβ- induced fibrosis and collagenase-induced OA-related fibrosis. For different fibrotic 
 diseases an increase in pyridinoline cross-links is reported, for instance in systemic  sclerosis, 
alcoholic cirrhosis, and glomerulosclerosis (26). Since these pyridinoline cross-links are 
 increased due to the elevated LH2b expression levels, we propose that LH2b is responsible 
for the persistence of fibrosis in OA. Most likely TGFβ, that is elevated in OA, is the driving 
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force of enhanced LH2b expression in the OA process. We and other groups have shown that 
blocking TGFβ prevents fibrosis (13,42). However, complete blockage of TGFb in OA is not 
an option as it is crucial for cartilage maintenance and repair. Selective blocking of LH2b in 
an early stage of OA may prevent the formation of pyridinoline cross-links, and therefore 
persistent fibrosis. This makes LH2b an interesting target for the treatment of OA-related 
synovial fibrosis. 
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Abstract 
Introduction: Synovial fibrosis is often present in osteoarthritis (OA) patients and may 
 greatly contribute to joint stiffness. Previously we found that procollagen-lysine, 2-oxoglu-
tarate 5-dioxygenase 2 (Plod2b), a collagen cross-linking enzyme was highly upregulated 
in  different OA-related fibrotic conditions in the synovium. Based on its function, Plod2 
might be  responsible for the persistence of synovial fibrosis. Therefore we want to investigate 
whether Plod2b is responsible for the persistence of synovial fibrosis.
Methods: We intra-articular injected Ad-CTGF, Ad-Plod2b or a combination of both in the 
right knee joint of mice. At day 5, 13 and 27 we isolated synovial biopsies for gene expression 
and cross-link measurement and whole knee joints for histology.
Results: Exposing the synovium to CTGF or a combination of CTGF + Plod2b increased 
the thickness of the synovium compared to controls. Col5a1 was significantly upregulated by 
overexpressing Ad-hPlod2b, Ad-CTGF or the combination of both. Moreover, Col5a1 mRNA 
expression was significantly correlated with both Ad-Plod2b and Ad-CTGF expression. All 
our selected OA-related fibrotic genes (Plod2b, Col1a1, Col5a1, Lox and Timp1) significantly 
correlated with each other. In none of the tested conditions the amount of pyridinoline cross-
links was altered in comparison with the control group, which suggests that the hPlod2b was 
not overexpressed high enough or did not function properly. 
Conclusion: To our knowledge, we show for the first time that both CTGF and Plod2b 
are able to induce Col5a1, one of our other selected OA-related fibrotic genes, which may 
 provide new insight in OA-related synovial fibrosis. However, valid conclusions about the 
role of Plod2b in the persistence of synovial fibrosis can only be drawn when PLOD2b can 
 specifically and functionally overexpressed or inhibited and lead to more or less pyridinoline 
cross-links respectively. 
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Introduction
Synovial fibrosis is a common problem amongst osteoarthritis (OA) patients. The excessive 
deposition of the extracellular matrix caused by the fibrotic process makes the synovial tissue 
thicker and more rigid (1). Therefore, synovial fibrosis may greatly contribute to joint stiff-
ness, one of the main symptoms of OA (2, 3). The key triggers for fibrosis are inflammation 
and tissue damage, which are both present in OA and might initiate the synovial fibrosis (4). 
TGFβ, which is enhanced and activated during these processes is the main inducer of the 
fibrotic cascade, but cannot be blocked in an OA joint without undesirable side effects due to 
its necessity for maintenance of cartilage (5). 
In our previous studies we searched for targets downstream of TGFβ for preventing 
OA-related fibrosis without interfering with joint homeostasis. We found that the collagen 
crosslinking enzyme PLOD2b, which activity leads to an elevation in pyridinoline cross link 
formation, was highly elevated in fibrotic synovial tissue. We confirmed that  these pyridi-
noline cross-links as well as Plod2b expression were elevated in the synovium of mice 
with  collagenase-induced OA (6). The degree of pyridiniline cross-links influences the 
 susceptibility of collagen to enzymatic degradation and therefore may cause the persistent 
fibrosis (7, 8). Because Plod2 based on its function does not negatively affecting joint homeo-
stasis, we  concluded from these studies that Lysyl hydroxylase 2b (Plod2b) is the most suitable 
target for interfering with OA-related fibrosis (6, 9). However, we do not have direct evidence 
that Plod2b is indeed involved in the onset and maintenance of synovial fibrosis. 
Plod2b is responsible for crosslinking of developing collagen, but does not induce collagen 
by itself. Therefore, in order to investigate its role in making collagen persistent to  degradation, 
we require an additional factor in our experiments that induces collagen production without 
elevated crosslinking capacity. TGFβ is a potent inducer of Plod2b and therefore not suitable 
for our experiment. CTGF, which causes transient synovial fibrosis, does not increase Plod2b 
and is thus a suitable candidate to co-injected with Plod2b (6, 10).
Therefore we intra-articularly (i.a.) injected an adenovirus (Ad) overexpressing CTGF 
(Ad-CTGF), Plod2b (Ad-Plod2b) or a combination of both in the right knee joint of mice. 
By performing this experiment we can investigate whether Plod2b increases the amount of 
pyridinoline cross-links and if this enables the transition from transient fibrosis, which is 
normally induced by CTGF, into persistent fibrosis, due to the additional presence of Plod2b. 
Furthermore, we can elucidate whether it affects and or correlates with, the gene expres-
sion  levels of other OA-related fibrotic genes (Col1a1, Col5a1, Lox and Timp1), so we can 
 determine whether Plod2 influences fibrosis by more than one mechanism (6, 9). 
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Materials and Methods
Animals
Twelve-week-old male C57BL/6J mice were used for animal studies. The mice were kept 
in  filtertop cages with wood chip bedding. They were fed a standard diet with tap water ad 
 libitum. All animal experiments were approved by the Radboud University Nijmegen Medical 
Centre Committee on Animal Research and Ethics.
CTGF and Plod2b overexpression
To investigate if Plod2b can enhance pyrodinoline cross linking and thereby cause  persistent 
fibrosis and whether it effects other OA-related fibrotic genes, right knee joints were  intra 
 articular injected with adenoviruses Ad-hPlod2b and/or Ad-hCTGF and/or Ad-Luc as a con-
trol. Mice were injected with 0,5 × 10e7 plaque-forming units (pfu) Ad-hPlod2b + 0,5 × 10e7 
pfu Ad-Luc in 6 μl 0.9% NaCl (Fresenius Kabi), 0,5 × 10e7 pfu Ad- hCTGF + 0,5 × 10e7 pfu 
Ad-Luc, 0,5 × 10e7 pfu Ad-hPlod2b + 0,5 × 10e7 pfu Ad-hCTGF or 1 × 10e7 pfu Ad-Luc 
alone as control. In the remainder of the article the Ad-hPlod2b + Ad-Luc and Ad-CTGF + 
Ad-Luc group are referred to as the Ad-Plod2b and Ad-CTGF. The mice were sacrificed on 
day 5, 13 and 27 after injection. Two synovial biopsies were isolated per mouse from the right 
knee joint, which were used for cross-link measurement and for mRNA isolation (n = 6 per 
group). Whole knee joints were isolated for histology (n = 6 per group). Since the adenovirus-
es overexpressed the human equivalent of Plod2b and CTGF we could distinguish these from 
endogenous murine Plod2b and Ctgf with specific primer sets (Table 1).
Isolation of mRNA from murine synovial tissue
For mRNA isolation, murine synovial tissue samples were placed in 1 ml Tri Reagent (Sigma) 
in MagNA Lyser Green Beads tubes (Roche) and disrupted in the MagNA Lyser for 4 cycles of 
20 seconds at 6,500 rpm with 1 minute of cooling on ice between cycles. The Tri Reagent was 
transferred to a 1.5 ml eppendorf tube and 200 μl chloroform was added. After 3 minutes of 
incubation the suspensions were centrifuged at 11,000 revolutions per minute for 15 minutes 
at 4°C. Supernatants (450 μl) were obtained and mixed with 450 μl isopropanol. This mixture 
was incubated for 10 minutes at room temperature and subsequently centrifuged at 11,000 
rpm for 10 minutes at 4°C. The RNA pellets obtained were washed twice with 75% ethanol, 
dried, and dissolved in 10 μl RNase-free water (Fresenius Kabi). To remove chromosomal 
DNA contamination in the isolated mRNA samples, the samples were treated with DNase I 
(Invitrogen).
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Reverse transcription–polymerase chain reaction (RT-PCR).
Isolated mRNA was transcribed into cDNA for quantitative PCR (qPCR). Eleven microliters 
(1 μg) of mRNA was mixed with 9 μl RT-PCR mix (1.9 μl distilled water, 2.4 μl 10× DNase 
buffer, 2.0 μl 0.1M dithiothreitol, 0.8 μl dNTPs (each at 12.5M), 0.4 μl oligo(dT) primer (0.5 
μg/μl), 1.0 μl reverse transcriptase (200 μg/μl; Invitrogen), and 0.5 μl RNasin (Promega). The 
RT-PCR protocol was as follows: 5 minutes at 25°C, followed by 60 minutes at 39°C and a final 
step of 5 minutes at 94°C. After the RT-PCR procedure, the cDNA was diluted 20 times for 
further use in qPCR analysis.
Quantitative PCR
For qPCR, a primer mix consisting of 1 μl (2.5 μM) forward and reverse primer was added 
to 5 μl SYBR Green Master Mix (Applied Biosystems). Thereafter, 3 μl cDNA was added and 
the qPCR was run on a StepOnePlus Real-Time PCR System according to manufacturer’s 
protocol (Applied Biosystems). The used primer sets are displayed in Table 1. Ct values of the 
genes of interest were corrected for reference gene GAPDH (delta Ct) and normalized against 
the delta-Ct of the non-stimulated sample (delta delta Ct).
Table 1. Primers used for Q-PCR. Primers were accepted if the deviation from slope of the standard 
curve was less than 0.3 compared to the slope of GAPDH standard curve and if the melting curve 
showed only one product. The optimal annealing temp of each primer pair was 57 ±5 oC. (h = human 
primer, m = murine primer)
Gene Forward primer 5’—3’ Reverse primer 5’—3’
hCTGF GTGGCCGACCCCTACTACATCC AGCAGCACCCTGTGATCATAATCTC
hPLOD2b TTAAAGGAAAGACACTCCGATCA-
GAGATGA
AATGTTTCCGGAGTAGGGGAGTCTTTTT
mCol1a1 TGACTGGAAGAGCGGAGAGTACT CCTTGATGGCGTCCAGGTT
mCol5a1 GCCCTCAGGGGTAACGAAAAC GACTCGGTAGGCAACATCCG
mGapdh GGCAAATTCAACGGCACA GTTAGTGGGGTCTCGCTCCTG
mLox TCTTCTGCTGCGTGACAACC GAGAAACCAGCTTGGAACCAG
mPlod2b CCGCAATGCTAGAGATATGACCTT CATTTGGAATGTTTCCGGAGTAG
mTgfβ GCAGTGGCTGAACCAAGGA AAGAGCAGTGAGCGCTGAATC
mTimp1 CAACTCGGACCTGGTCATAAGG CATCTTGATCTTATAACGCTGGTATAAGG
Cross-link measurement
Synovial tissue samples (n = 6 per group) were hydrolyzed in an oven with 6 M HCl at 110°C 
for 20 h. After drying (Speed Vac) samples were dissolved in 100 μl internal standard. The 
amount of hydroxyproline (Hyp) and the cross-links lysylpyridinoline (LP) and hydroxylysyl 
pyridinoline (HP) in these samples were determined by reversed-phase high-performance 
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liquid chromatography (HPLC) as described by Bank et al. (11). To calculate the amount of 
HP per triple helix the amount of HP (pmol) in the sample was divided by the total amount of 
collagen (=Hyp/300). Values are expressed as total amount of residues per collagen molecule, 
assuming 300 Hyp residues per triple helix.
Histology and immunohistochemistry
The murine knee joints were processed and sectioned in 7 µm frontal sections as  previously 
described (12). Subsequently the sections were stained with Safranin O–fast green. The 
 thickness of the synovium was measured as a parameter for fibrosis, by drawing a line from 
the bone covering the synovium to the outer layer of the synovium whilst omitting parts that 
do not cover the synovium. The total width of the line covering the synovium is used as a 
measure for synovial thickness. The location of measurement was lateral of the growth plates 
in the femur on three locations evenly distributed along the width of the growth plate. We 
measured these 3 locations in 2 sections per knee joints (Figure 1b). The average value per 
knee joint was used for further calculations.
Statistical analysis
First all data were checked for normality with the Shapiro-Wilk test. To determine significant 
(P<0.05) differences between groups that were normally distributed a One-Way ANOVA with 
Bonferroni post hoc test for multiple comparison was performed when equal variances were 
assumed otherwise the Games-Howell post hoc test for multiple comparison was performed. 
For the correlations a Pearson correlation of ≥ 0.6 was chosen as cutoff value, as we were only 
interested in strong correlations The statistical analyses were performed with the statistical 
software package SPSS 20.0 (SPSS, Chicago, IL, USA). 
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Results
Before we examined whether and how hPlod2b, influences CTGF-induced synovial  fibrosis 
we checked whether the adenoviruses induced expression of hPlod2b and hCTGF in the 
 synovium of murine right knee joint where the adenoviruses were intra-articular injected. 
This showed a clear but moderate expression of both hPlod2b and hCTGF until at least day 
27 (Table 2).
Table 2. Ct values of hPlod2b and hCTGF in the synovium after overexpressing hCTGF, hPlod2b or a 
combination of both. Mice were injected i.a. with an adenovirus encoding either hPlod2b or hCTGF or 
a control virus (Luciferase (Luc)). Five, 13 and 27 days after injection of the adenovirus synovial biopsy 
punches were isolated for mRNA extraction. Primers detecting only human Plod2b and human CTGF 
were used to evaluate whether expression was sustained over a period of time. Ct values were corrected 
for Gapdh. Higher Ct values represent a lower expression. Nd = not detectable. Human Plod2b was only 
found in synovial biopsy punches of mice injected with Ad-hPlod2b whereas hCTGF was only detected 
in synovial biopsy punches of mice injected with Ad-hCTGF. The expression levels declined in time, but 
was still detectable at day 27 
Human PLOD2B Human CTGF
Ad-Luc day 5 Nd Nd
Ad-Luc day 13 Nd Nd
Ad-Luc day 27 Nd Nd
Ad-PLOD2B + Ad-Luc day 5 13,2 Nd
Ad-PLOD2B + Ad-Luc day 13 14,9 Nd
Ad-PLOD2B + Ad-Luc day 27 16,4 Nd
Ad-CTGF + Ad-Luc day 5 Nd 15,5
Ad-CTGF + Ad-Luc day13 Nd 19,0
Ad-CTGF + Ad-Luc day 27 Nd 17,5
Ad-PLOD2B + Ad-CTGF day5 11,3 12,2
Ad-PLOD2B + Ad-CTGF day 13 14,5 19,5
Ad-PLOD2B + Ad-CTGF day 27 14,8 19,0
CTGF increases the thickness of the synovium at both day 13 and 27 
We compared the thickness of the synovium between the Plod2b, CTGF and the  combination 
group to examine whether Plod2b can make fibrosis, induced by CTGF, persistent  (Figure 1). 
As  expected, there were no differences in synovial thickness between the Ad-Plod2b and Ad-
Luc control group. In the Ad-CTGF group the synovium was thicker compared to the control 
group on day 13 (p = 0,001). However, when comparing CTGF groups in time we found 
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that on both day 13 (p = 0.002) and 27 (p = 0.020) the synovium was thicker compared to 
day 5. Also in the CTGF + Plod2b group the synovium was significantly thicker on day 13 
(p = 0.036) compared to the control group. There were no significant differences between 
CTGF and the CTGF + Plod2b group at any of the measured time points. Moreover, we only 
 observed a limited induction of fibrosis by CTGF and this was not reversible within the 27 
days of the experiment.
Figure 1. [a] Thickness of the synovium in µm, average of three measurements lateral of the growth 
plate as indicated on figure 1 [b]. * p = ≤ 0.05 ** p = ≤ 0.005 
Col5a1 was significantly upregulated by overexpressing hPlod2b, hCTGF or the 
 combination of both.
In our prior studies, we found there were 5 genes of high importance in synovial fibrosis and 
related to OA. Therefore, we investigated whether these “OA-related fibrotic genes” (Plod2b, 
Col1a1, Col5a1, Lox and Timp1) were affected by CTGF, Plod2b or the combination of both 
(Figure 2). Col5a1 mRNA was significantly upregulated at day 5, after overexpressing Ad-
hPlod2b (p = 0.024) and the combination of Ad-hPlod2b and Ad-CTGF (p= 0.006)  compared 
to  Ad-Luc. At day 13 Col5a1 mRNA was still significantly upregulated when Ad-Plod2b and 
Ad- CTGF  (p = 0.024) were co-expressed, but no longer by Plod2b alone. Allthough Ad- CTGF 
did not have an impact on Col5a1 at day 5, we did observe a significant upregulation by day 
13 (p = 0.046). None of the measured genes was significantly different at day 27 between the 
Ad-Plod2b, Ad-CTGF or Ad-Plod2b + Ad-CTGF group and the control group (Ad-Luc). 
 Furthermore, there were no significant differences between the Ad-Plod2b, Ad-CTGF and 
Ad-Plod2b + Ad-CTGF group at any of the measured time points. 
 B Patella 
Place of measurement 
synovial thickness 
Femur 
 * 
** 
** 
* [A] [B]
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Figure 2. mRNA expression of Col1a1, Col5a1, Plod2b, Lox and Timp1 in murine synovium 5, 13 and 
27 days after i.a. injection of Ad-CTGF, Ad-Plod2b or Ad-CTGF + Ad-Plod2b. * p = ≤ 0.05
[A] Ad-LH2b
[B] Ad-CTGF
[C] Ad-LH2b + Ad-CTGF
*
*
*
*
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Col5a1 significantly correlates with both Ad-Plod2b and Ad-CTGF expression.
Because there was quite some spread in the hPlod2b and hCTGF gene expression levels in the 
synovial samples, which could have a major impact on the final outcome of the experiments, 
we decided to investigate whether the height of the measured fibrotic genes was affected by 
the expression of the overexpressed genes. Ad-hPlod2b significantly correlated with mCol5a1 
and mTimp1 whereas Ad-hCTGF correlated with mCol5a1 and mPlod2b (Table 3). These 
findings are in line with the elevated Co51a1 gene expression levels due to the Plod2b and/or 
CTGF overexpression.
Table 3. Pearson correlation between Ad-hPlod2b or Ad-hCTGF and the fibrotic genes Plod2b, Col1a1, 
Col5a1, Lox and Timp1.
mCol1 mCol5 Plod2b LOX Timp1
Ad-hPlod2b Pearson Correlation 0.426 0.618 0.506 0.582 0.645
Sig. (2-tailed) 0.78 0.006 0.032 0.11 0.004
N 18 18 18 18 18
Ad-hCTGF Pearson Correlation 0.202 0.638 0.667 0.468 0.475
Sig. (2-tailed) 0.488 0.14 0.009 0.092 0.086
N 14 14 14 14 14
Correlation of Mouse with Mouse genes.
To get more insight in whether our selected OA-related fibrotic genes are associated with 
each other, we studied how their endogenous gene expression levels correlated. Because 
the  correlations between mPlod2b or mCtgf and the other genes can be influenced by the 
 presence of hPlod2b and hCTGF these correlations were not investigated. With the  exception 
of the correlation between mCol5a1 and mTimp1, all other correlations between mCol1a1 
 mCol5a1, mTgfβ, mLox and mTimp1 had a Pearson correlation above 0.6, and therefore 
strongly correlate with each other (Table 4). 
Table 4. Pearson correlation between the endogenous levels of our top of OA-related fibrotic genes 
(Col1a1, Col5a1, Lox and Timp1).
mCol1 mCol5 mTgfβ mLox mTimp1
mCol1 Pearson Correlation - 0.672 0.686 0.701 0.793
Sig. (2-tailed) - <0.001 <0.001 <0.001 <0.001
N - 66 66 66 66
mCol5 Pearson Correlation 0.672 - 0.602 0.840 0.550
Sig. (2-tailed) <0.001 - <0.001 <0.001 <0.001
N 66 - 66 66 66
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mCol1 mCol5 mTgfβ mLox mTimp1
mLox Pearson Correlation 0.701 0.840 0.719 - 0.603
Sig. (2-tailed) <0.001 <0.001 <0.001 - <0.001
N 66 66 66 - 66
mTimp1 Pearson Correlation 0.793 0.550 0.759 0.603 -
Sig. (2-tailed) <0.001 <0.001 <0.001 <0.001 -
N 66 66 66 66 -
The amount of pyridiniline cross-links is not changed by overexpressing Ad-hPlod2b, 
Ad-CTGF or the combination of both.
On histology we expected that the combination of Plod2b and CTGF would give the highest 
amount of fibrosis at least from day 13 on. However, the CTGF group with the exception of 
day 5, did not differ from the combination of CTGF with Plod2b. Therefore, we measured 
whether the increased Plod2b expression indeed resulted in more pyridinoline cross-links 
in the synovium as anticipated (Figure 3). In the Ad-Plod2b group, the amount of pyridi-
noline cross-links at day 13 was lower compared to day 5 (p = ≤ 0.0005) and day 27 (p = ≤ 
0.0005), but also compared to day 13 (p = 0.016) of the Ad-CTGF group. These results were 
 unexpected as we expected an increase of pyridinoline cross-links in the Ad-Plod2b groups. 
However, this does  explain the lack of anticipated effects of Plod2b on synovial thickness. 
Figure 3. HPLC cross-link measurement in synovial punches, obtained from mice after overexpression 
of Ad-Luc, Ad-Plod2b, Ad-CTGF, and Ad-Plod2b + Ad-CTGF (n = 6 per group). only at day 13 the 
amount of pyridinoline cross-links in the Ad-Plod2b group was significant lower compared to day 5 and 
day 27 of the Ad-Plod2b group and compared to day 13 of the Ad-CTGF group. 
* p = ≤ 0.05 ** p = ≤ 0.005 *** p = ≤ 0.0005.
 
*** 
* 
*** 
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Discussion
In this study we set out to investigate the role of Plod2b in the onset and maintenance of 
 synovial fibrosis. We expected to find an increase in synovial fibrosis when combining CTGF 
and Plod2b when compared to CTGF alone. Unfortunately, this did not happen, which we 
consider due to technical issues. First of all, we did not observed the same fibrotic pattern 
we found in our previous Ad-CTGF experiment (10). In the current study CTGF resulted 
in less synovial thickening and was not reversed by day 27, as observed in the previous ex-
periments (6, 10). We do not expect the slight differences in timing between the current ex-
periment and our prior study to be an issue here. The fact that we used half of the viral load 
of Ad-CTGF compared to our prior study, could play a role as this resulted in less than half 
of the CTGF gene expression found in the previous experiment. We could not circumvent 
this as this was necessary to keep all groups comparable to the Ad-Plod2b + Ad-CTGF in 
terms of total viral load of 1 × 10e7 pfu. We expected an increased pyrodinoline cross linking 
when Plod2b was added to CTGF, but this was not the case, which suggests that the hPlod2b 
was not over expressed high enough or did not function properly. This might be due to the 
improper protein translation of the hPlod2b gene or incorrect protein folding resulting in an 
inactive enzyme. Another, less likely possibility is that the human Plod2b does not function 
in mice. Given the high homology of human and mouse Plod2b this is rather unexpected. The 
Adeno virus only target the synovial lining, which is only one till three cell layers thick and 
thus a small proportion of the synovium. Because Plod2b is an intracellular enzyme, Plod2b 
will only be overexpressed in the synovial lining and can only have an effect in the transfected 
cells. This may not be enough to make a substantial difference in the amount of pyridinoline 
cross-links in the synovium. 
We propose that we can answer this question by a slight modification in the future setup. 
First we need to ensure that the Ad-Plod2b is transcribed in an active enzyme. This can be 
achieved by overexpressing it in murine fibroblasts and measure the amount of pyridinoline 
cross-links after several weeks of culturing. When the Ad-Plod2b proves to be functional, the 
in vivo experiment can be repeated but with double the viral load and with the same time 
points as the previous CTGF experiment (day 3, 7 and 28). This doubling of the viral load is 
required to obtain comparable CTGF expression levels as in the previous experiment, which 
showed the desired fibrotic profile (6, 10). The only potential problem with this is that the 
higher total viral load might lead to unwanted side effects. 
Despite the unexpected limitations of our study, we were able to identify that Plod2b, 
Col1a1, Col5a1, Lox and Timp1 strongly correlates with each other in this experiment. These 
strong correlations suggest that these fibrotic genes are most likely regulated via the same 
 factors. TGFβ is one of these factors and is assumable the main cause of the correlations as 
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all the measured fibrotic genes are regulated via TGFβ-signaling and as TGFβ is the main 
 inducer of these genes. However, because Ad-Plod2b and Ad-CTGF were able to induce 
 Col5a1 expression and both are strongly correlated with Col5a1 expression, there might also 
a direct effect of CTGF and Plod2b on Col5a1 expression. Also Ad-CTGF and Plod2b were 
highly correlated, but we know from this and previous experiment that Plod2b is not induced 
by CTGF, suggesting that these two genes are probably correlated via TGFβ.
We show, for the first time, that CTGF and Plod2b are able to induce Col5a1. These results 
indicate that inhibition of Plod2b or CTGF also may lower the Col5a1 expression in some 
extend, as they are both inducers of Col5a1. Type V Collagen is a regulatory fibril-forming 
collagen that forms heterotypic fibrils with collagen I (13). Moreover, depletion of type V 
Collagen leads to dysfunctional regulation of fibrillogenesis. However, the importance of type 
V Collagen in collagen fibril formation its role in fibrosis is not yet examined, there are some 
clues that it may play a role in the maintenance of fibrosis. This beacause it is published that 
α1(V)-N-propeptide domain of type V collagen is able to bind TGFβ and MMP2 among 
other things. This may lead to a local increase of active TGFβ, as more of these α1(V)-N-pro-
peptide domain will be present in the synovium due to the increased Col5a1 expression, and 
 sustaining the fibrotic cascade. 
Unfortunately, valid conclusions about the role of Plod2b in synovial fibrosis can only be 
drawn when Plod2b can specifically en functionally overexpressed or inhibited and result in 
more or less pyridinoline crosslinks in the synovium.
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Abstract 
Lysyl hydroxylase 2b (LH2b) is known to increase pyridinoline cross-links, making collagen 
less susceptible to enzymatic degradation. Previously, we observed a relationship between 
LH2b and osteoarthritis-related fibrosis in murine knee joint. 
For this study, we investigate if transforming growth factor-beta (TGFβ) and connective 
tissue growth factor (CTGF) regulate procollagen-lysine, 2-oxoglutarate 5- dioxygenase 2 
(PLOD2) (gene encoding LH2b) and LH2b expression differently in osteoarthritic human 
synovial fibroblasts (hSF). Furthermore, we investigate via which TGFβ route (Smad2/3P or 
Smad1/5/8P) LH2b is regulated, to explore options to inhibit LH2b during fibrosis.
To answer these questions, fibroblasts were isolated from knee joints of osteoarthritis 
 patients. The hSF were stimulated with TGFβ with or without a kinase inhibitor of ALK4/5/7 
(SB-505124) or ALK1/2/3/6 (dorsomorphin). TGFβ, CTGF, constitutively active (ca)ALK1 
and caALK5 were adenovirally overexpressed in hSF. The gene expression levels of PLOD1/2/3, 
CTGF and COL1A1 were analyzed with Q-PCR. LH2 protein levels were  determined with 
western blot. 
As expected, TGFβ induced PLOD2/LH2 expression in hSF, whereas CTGF did not. 
PLOD1 and PLOD3 were not affected by either TGFβ or CTGF. SB-505124 prevented the 
induction of TGFβ-induced PLOD2, CTGF and COL1A1. Surprisingly, dorsomorphin 
 completely blocked the induction of CTGF and COL1A1, whereas TGFβ-induced PLOD2 
was only slightly reduced. Overexpression of caALK5 in osteoarthritic hSF significantly 
 induced PLOD2/LH2 expression, whereas caALK1 had no effect. 
We showed, in osteoarthritic hSF, that TGFβ induced PLOD2/LH2 via ALK5 Smad2/3P. 
This elevation of LH2b in osteoarthritic hSF makes LH2b an interesting target to interfere 
with osteoarthritis-related persistent fibrosis.
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Introduction
Osteoarthritis (OA) is the joint disease with the highest incidence. The hallmarks of 
 osteoarthritis are cartilage degeneration, osteophyte formation and fibrosis, with as main 
symptoms joint pain and joint stiffness. Osteoarthritis-related fibrosis is characterized by 
 fibroblast proliferation and excessive deposition of extracellular matrix components such 
as collagen.This excessive deposition of collagen leads to thickening and stiffening of the 
 synovial membrane making synovial fibrosis a major contributor to joint stiffness and pain 
in osteoarthritis-affected joints (1). The response by fibroblasts toward soluble  mediators, 
in  particular transforming growth factor beta (TGFβ) and connective tissue growth factor 
(CTGF), is thought to be the key event in the onset and progression of fibrosis (2). TGFβ 
was found to be highly expressed in fibrotic organs suggesting a major role in fibrosis (3, 4). 
Furthermore, tissue-specific overexpression of TGFβ1 in transgenic mice resulted in lung, 
liver or skin fibrosis, whereas blocking TGFβ in osteo arthritis resulted in strong reduction of 
synovial fibrosis (5, 6).
When TGFβ binds the TGFβ type II receptor (TGFßR-II), they form a complex that 
 recruits the TGFβ type I receptor, activin receptor-like kinase 5 (ALK5) (7). ALK5 then 
phosphorylates the receptor-Smads (R-Smads), Smad2 and Smad3.  Activated R-Smads form 
heteromeric complexes with Smad4 and translocate to the nucleus, to  regulate the expression 
of target genes. Other than phosphorylation of Smad2/3 (Smad2/3P) via ALK5, TGFβ can 
also give rise to Smad1/5/8P (8).There is evidence that, depending on the cell type, TGFβ can 
induce Smad1/5/8P via ALK5 alone or via a complex containing both ALK5 and ALK1 (9, 10). 
Importantly,  depending on the ALK1/ALK5 ratio, TGFβ will induce different downstream 
effects (8, 11). 
It has been previously shown by our group and other groups that overexpressing TGFβ 
leads to persistent fibrosis, whereas CTGF induces transient fibrosis (12-16). We recently 
 investigated what caused this difference in persistence between TGFβ- and  CTGF-induced 
fibrosis in the synovium of mice. Changes in collagen synthesis levels and protease expression 
could not explain this difference (17). In fact, TGFβ  stimulation resulted in elevated  expression 
levels of MMP3 ,9 and 13, whereas CTGF had a minor influence on MMP  expression. Since 
alterations in collagen cross-linking can have an impact on collagen degradation, we investi-
gated the lysyl hydroxylases. Lysyl hydroxylases are enzymes that catalyze the hydroxylation 
of lysine into hydroxylysine and, therefore, fulfill a crucial role in collagen modification and 
cross-linking (18, 19). Comparing TGFβ- and CTGF-induced synovial fibrosis revealed that 
TGFβ overexpression resulted in a major increase in Lysyl hydroxylase 2b (LH2b) expression, 
whereas CTGF did not change LH2b expression in murine knee joints (17). LH2b is respon-
sible for the overhydroxylation of collagen telopeptides, which will result in more hydroxy-
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allysine-derived cross-links such as pyridinolines (18). These cross-links are more resistant 
to degradation than lysine-associated cross-links and have been found  elevated in various 
fibrotic diseases such as systemic sclerosis, lipodermatosclerosis, alcoholic cirrhosis, glome-
rulosclerosis and interstititial fibrosis (20, 21). Furthermore, in experimental osteoarthritis, 
we found an increase in LH2b expression as well as an increase in the number of pyridinoline 
cross-links per triple helix. Therefore, a causal relationship between LH2b and irreversible 
fibrosis in osteoarthritis is plausible. 
In this study, we investigate whether PLOD2 (the gene encoding for splice variants LH2a 
and LH2b) expression and LH2b protein were upregulated by TGFβ in human osteoarthritic 
fibroblasts. Furthermore, we investigate which TGFβ signaling route induces LH2b  expression 
in human synovial fibroblasts. This could enable identification of potential targets to block 
 osteoarthritis-related fibrosis.
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Materials and methods
Cell culture
Synovial fibroblasts were isolated from synovial tissue obtained from osteoarthritis patients 
that underwent knee joint arthroplasties. This synovial tissue was separated from fat,  tendon 
and ligamental tissue and then cut into small pieces of approximately 3 mm3, which were 
placed into a six-well plate (3 pieces per well). The fibroblasts were allowed to grow out of the 
tissue and proliferate for 4 weeks before they were transferred into a culture flask. The fibro-
blasts were cultured in monolayer in Basal Medium Eagle (BME) medium (Invitrogen, Gibco, 
Carlsbad, CA, USA) enriched with 10 % FCS, gentamycin (50 μg/ml) and 1 %  pyruvate up to 
passage 10 (22) (see supplementary Figure S1).We measured type1 collagen (COL1A1) and 
 propyl-4-hydroxylase (P4H) expression as markers for fibroblasts. Before every experiment, 
the fibroblasts were cultured in serum-free medium for 24 h. Each experiment was performed 
in duplo using 4 different donors.
Blocking of TGFβ induced ALK1 and ALK5 signaling
To distinguish between ALK4/5/7 and ALK1/2/3/6 kinase activity, we used SB-505124  (Sigma, 
St. Louis, MO, USA) and dorsomorphin (BIOMAL International, Exeter, UK), which inhibits 
the kinase activity of these ALKs, respectively (23, 24). We tested dorsomorphin on its  ability 
to inhibit ALK1 signaling in  synovial  fibroblasts by adding dorsomorphin to fibroblasts that 
overexpressed constitutively active (ca)ALK1 and subsequently performed a western blot 
on Smad1/5/8P levels (see supplementary data Figure S2). Human synovial fibroblasts were 
 stimulated for 30 min, 24 and 48 h with 10 ng/ml TGFβ with and without 4 h pre-incubation 
with 5 μM SB-505124 or dorsomorphin.  Subsequently, the cells were lysed in TRI Reagent 
(Sigma) for mRNA isolation and subsequent Q-PCR  analyses or in lysis buffer for western 
blot analysis.
Adenoviral transduction
Human synovial fibroblasts were transduced with a multiplicity of infection (MOI) of 50 for 2 
h with adenoviruses overexpressing either TGFβ (Ad-TGFβ) or CTGF (Ad-CTGF) to  examine 
the effect of TGFβ on LH1, LH2b and LH3 mRNA expression. To study whether  these effects 
were ALK1- or ALK5-dependent, the fibroblasts were transduced with  constitutively active 
(ca)ALK1 (Ad-caALK1) or caALK5 (Ad-caALK5). CTGF was used to compare  transient 
 fibrosis to TGFβ-induced persistent fibrosis. Ad-Luc, an overexpressing luciferase, was used 
as a control virus. After 2 h, the transductionmix was replaced by serum-free medium and 
the cells were cultured for 24 h. Subsequently, the cells were lysed in TRI Reagent (Sigma) for 
Q-PCR analysis or in lysis buffer for western blot analysis.
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Quantitative PCR
Total RNA was isolated from the fibroblasts and treated with DNAse I (Invitrogen) to remove 
potential DNA contamination. The mRNA was reverse transcribed into cDNA and  subjected 
to quantitative real-time PCR (Q-PCR) on StepOnePlus (Applied Biosystems, Darmstadt, 
Germany). Each cDNA sample was amplified using specific primers for PLOD1/2b/3, CTGF 
and collagen type 1A1 (COL1A1) (Table 1). The total reaction volume of 20 μl contained 3 μl 
cDNA, 5 μl SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) and 1 μl (2.5 
μM) forward and reverse primer. The primer for PLOD2 specifically detected splice variant 
LH2b. All primers were accepted if the deviation from the slope of the standard curve was 
not higher than 0.3 compared to the slope of the GAPDH standard curve. In addition, the 
melting curve was required to show only one product. Ct values of the genes of interest were 
corrected for reference gene GAPDH (delta Ct) and normalized against the delta-Ct of the 
non-stimulated sample (delta delta Ct).
Table 1. Primers used for Q-PCR. Primers were accepted if the deviation from the slope of the  standard 
curve was less than 0.3 compared to the slope of GAPDH standard curve and if the melting curve 
 showed only one product. Efficiencies for all primer sets were determined using a standard curve of 5 
serial cDNA dilutions in water in duplicate
Name Forward primer Reverse primer
PLOD1 5’-CAAGCGCTCAGCTCAGT-
TCTTC-3’
5’-CTTCAGCAGCCGGACCTTCT-3’
PLOD2 
(LH2b)
5’-TTAAAGGAAAGACACTCC-
GATCAGAGATGA-3’
5’-AATGTTTCCGGAGTAGGG-
GAGTCTTTTT-3’
PLOD3 5’-CTGGGCCTGGGAGAG-
GAGTG-3’
5’-TCACGTCGTAGCTATCCA-
CAAACAT-3’
COL1A1 5’-GTGGAAACCCGAGCCCT-
GCC-3’
5’-TCCCTTGGGTCCCTCGACGC-3’
CTGF 5’-GCCCTCGCGGCTTACC-3’ 5’-AGGCAGTTGGCTCTAATCA-
TAGTTG-3’
GAPDH 5’-ATCTTCTTTTGCGTCGC-
CAG-3’
5’-TTCCCCATGGTGTCTGAGC-3’
Western blot analysis
For western blot analysis, the cells were washed twice with 0,9 % NaCl and lysed with  Lysis 
Buffer containing: 20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 
1 % Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4 and 
complete protease inhibitor cocktail (Roche Applied Science, Penzberg, Germany). Soluble 
proteins and cell membranes were separated by centrifugation (15,000g, 15 min, 4 °C). For 
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each sample, the protein concentration was measured with the BCA Protein Assay Reagent 
Kit (Pierce, Rockford, IL, USA). Equal amounts of each protein sample were loaded under 
 reducing conditions on a 7.5 % SDS-PAGE gel. After electrophoresis, the proteins were trans-
ferred onto a nitrocellulose membrane using the iBlot Dry Blotting System  (Invitrogen). 
The membrane was blocked according to the manufacturer’s protocol. Subsequently, the 
 membrane was incubated overnight at room temperature with antibodies directed against 
Smad2/3P or Smad1/5/8P (1:1,000) (Cell Signaling Technology, USA). For LH2 detection, 
the membrane was incubated for 1 h with anti-LH2 (1:1,000) (Proteintech, Manchester, UK). 
The secondary antibody used for α-Smad2/3P, α-Smad1/5/8P and α-LH2 was goat-anti-rabbit 
HRP (1:1,500) (Dako, Copenhagan, Denmark). Proteins were detected using the ECL Plus 
westernblotting detection system (GE Healthcare, Buckingham-shire, UK).
Statistical analysis
First, all data were checked for normality with the Shapiro–Wilk test. To determine  significant 
(P<0.05) differences between groups that were normally distributed, a one-way ANOVA 
with Bonferroni post hoc test for multiple comparison was performed. Significant (P<0.05) 
 differences between groups that were not normally distributed, were determined with the 
Wilcoxon Signed Ranks Test. The statistical analyses were performed with the statistical 
 software package SPSS 20.0 (SPSS, Chicago, IL, USA).
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Results
TGFβ induces both LH2b mRNA and LH2 protein expression in human synovial 
 osteoarthritic fibroblasts.
Previously, we have shown that TGFβ induces LH2b expression in the synovium of  murine 
knee joints (17). To investigate whether TGFβ had similar effects in  humans, we isolated 
 fibroblasts from synovial tissue obtained from osteoarthritis patients that  underwent knee 
joint arthroplasties. TGFβ was compared to CTGF to examine if there were  differences between 
these pro-fibrotic factors regarding PLOD gene expression in human synovial  osteoarthritic 
fibroblasts. Adenoviral TGFβ overexpression significantly induced PLOD2 (LH2b mRNA) 
expression, whereas PLOD1 and PLOD3 were not significantly altered compared with the 
adenoviral control Ad-Luc (Figure 1a). As expected, overexpression of adenoviral CTGF had 
no effect on PLOD1, PLOD2 or PLOD3 in human synovial fibroblasts. To confirm whether 
TGFβ also enhances LH2 protein expression, fibroblasts were stimulated with 10 ng TGFβ 
and subsequently harvested for western blot analysis. The LH2 protein levels were strongly 
increased after both 24 and 48 h of TGFβ stimulation confirming that the increased LH2b 
mRNA expression results in elevated LH2 protein levels (Figure 1b). In compliance with our 
previous results in mice, PLOD2 and LH2 protein expression were also induced in human 
synovial fibroblasts by TGFβ and not by CTGF stimulation.
Figure 1. 
TGFβ induces both PLOD2b mRNA and 
LH2 protein expression levels in human 
synovial fibroblasts. 
[a] PLOD2b mRNA expression in human 
synovial fibroblasts 24 h after transduc-
tion with Ad-TGFβ or Ad-CTGF. TGFβ 
 strongly induces PLOD2b, whereas PLOD1 
and PLOD3 were not  significantly affec-
ted by TGFβ. CTGF did not alter mRNA 
 expression of the different PLOD isoforms. 
[b] Human synovial fibroblasts were 
 cultured in the presence or absence of 
TGFβ for 24 and 48 h and harvested for 
western blot analysis. A strong increase in 
LH2 protein level was observed after both 
24 and 48 h TGFβ stimulation.
     
     LH2
     β-Actin
     
     C        24h     48h
[A]
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SB-505124 inhibits TGFβ-induced Smad2/3P and Smad1/5/8P.
We investigated whether Smad2/3P or Smad1/5/8P were required for TGFβ-induced LH2b 
expression. First, we investigated the capacity of SB-505124 and dorsomorphin to inhibit 
TGFβ-induced Smad2/3P and Smad1/5/8P in human synovial fibroblasts, by western blot 
analysis. In the absence of exogenous TGFβ, a moderate basal protein level of Smad1/5/8P 
was observed, whereas no basal protein levels for Smad2/3P were detected (Figure 2a). TGFβ 
stimulation increased both Smad2/3P and Smad1/5/8P protein levels. In contrast to the 
 basal Smad1/5/8P levels, which were completely inhibited by dorsomorphin, TGFβ- induced 
Smad1/5/8P was only partly reduced by dorsomorphin. SB-505124 strongly decreased 
TGFβ- induced Smad1/5/8P and completely blocked TGFβ-induced Smad2/3P. As expected, 
 dorsomorphin did not alter Smad2/3P protein levels. These results indicate that ALK4/5/7 
kinase activity is involved in both TGFβ-induced Smad2/3 and Smad1/5/8 phosphorylation.
Inhibition of ALK4/5/7 kinase activity prevents induction of LH2b in human synovial 
fibroblasts.
We determined whether ALK4/5/7 or ALK1/2/3/6 kinase activity was responsible for 
 increased PLOD2, CTGF and COL1A1 expression. Therefore, the human synovial fibro-
blasts were stimulated with TGFβ alone or TGFβ with SB-505124 or dorsomorphin. TGFβ 
 stimulation significantly induced LH2b, COL1A1 and CTGF mRNA expression in human 
synovial  fibroblasts (Figure 2b). PLOD1 and PLOD3 mRNA expression were not  significantly 
affected by TGFβ. Also, blocking the ALK4/5/7 or ALK1/2/3/6 kinase activity with SB-505124 
or  dorsomorphin, respectively, had no significant effects on PLOD 1 or PLOD3 mRNA 
 expression. SB-505124 completely blocked TGFβ-induced LH2b, COL1A1 and CTGF mRNA 
expression. Similar to SB-505124, dorsomorphin also fully blocked TGFβ-induced COL1A1 
and CTGF. In contrast to SB-505124, LH2b mRNA expression was still significantly up-
regulated by TGFβ in the presence of dorsomorphin (Figure 2b). These results demonstrate 
that TGFβ-induced LH2b is mainly dependent on ALK4/5/7 kinase activity.
Figure 2. 
[a] TGFβ both induces Smad2/3P 
and Smad1/5/8P in human synovial 
 fibroblasts. SB-5 blocks both TGFβ- 
induced Smad2/3P and Smad1/5/8P, 
whereas DM only partially blocks 
TGFβ-induced Smad1/5/8P and has 
no effect on Smad2/3P. 
[A]
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Overexpressing caALK5 but not caALK1 induces LH2b mRNA and LH2 protein in  human 
synovial fibroblasts.
To confirm that LH2b is ALK5- and not ALK1-dependent, we investigated the effect of caALK1 
and caALK5 on PLOD1, PLOD2 and PLOD3 gene expression. Overexpression of caALK5 
 significantly induced LH2b mRNA expression. In contrast, over expressing caALK1 did not 
alter LH2b mRNA expression (Figure 3). Neither PLOD1 nor PLOD3 mRNA  expression were 
affected by overexpressing either caALK1 or caALK5. Also, LH2 protein was  elevated after 
overexpression of caALK5, whereas caALK1 had no effect. These results show that PLOD2/
LH2 is induced via ALK5 and not via ALK1 signaling in human synovial fibroblasts.
Figure 3. [a] mRNA expression of PLOD1, PLOD2b and PLOD3 in human synovial fibroblasts, 24 h 
after transduction with Ad-caALK1 or Ad-caALK5. Whereas overexpressing caALK5 induces PLO2b, 
caALK1 has no effect on PLOD2b mRNA expression. Neither PLOD1 nor PLOD3 were affected by 
caALK1 or caALK5. [b] LH2 protein expression was elevated after Ad-caALK5 overexpression but not 
after overexpression of Ad-caALK1.
     
     LH2
     Smad1/5/8P
     Smad2/3P
     GAPDH
[A] [B]
Figure 2. 
[b] mRNA expression of PLOD1, 
PLOD2b, PLOD3, CTGF and COL1A1 
in human synovial fibroblasts 24 h  after 
TGFβ stimulation with and without 
4 h pre-incubation with SB-5 or DM. 
Inhibition of ALK4/5/7 kinase  activity 
with SB-5, fully blocks the  induction 
of PLOD2b by TGFβ. Blocking the 
ALK1/2/3/6 kinase activity with DM, 
only slightly reduces TGFβ-induced 
PLOD2b.
[B]
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TGFβ dose-dependently induces Smad2/3P and Smad1/5/8P but this does not influence 
the height of the LH2b mRNA expression level.
We investigated dose-dependent induction of Smad1/5/8P and/or Smad2/3P levels and the 
subsequent effect on LH2b regulation. Therefore, human synovial fibroblasts were  stimulated 
with a concentration range from 0 to 15 ng TGFβ. Smad1/5/8P increased along with the TGFβ 
concentration, whereas Smad2/3P decreased as the TGFβ concentration increased  (Figure 
4a). High TGFβ concentrations (7.5 ng and higher) favored Smad1/5/8P, whereas lower 
TGFβ concentrations of approximately 0.63–5 ng favored Smad2/3P in human osteo arthritic 
fibroblasts. To examine whether a low (1 ng) TGFβ concentration increased LH2b mRNA 
 expression rather than a high (20 ng) TGFβ concentration, the LH2b mRNA expression was 
determined after 24 h stimulation with 1 and 20 ng TGFβ. To study if blocking the Smad2/3 
or Smad1/5/8 route modulated the LH2b expression, the TGFβ stimulation was performed 
with and without the presence of dorsomorphin and SB-505124. No differences between 1 
and 20 ng TGFβ were found on LH2b mRNA expression with or without the  SB-505124 or 
dorsomorphin (Figure 4b).
Figure 4. [a] Smad 1/5/8P increases with higher TGFβ concentrations whereas Smad 2/3P decreases 
at higher TGFβ concentration in comparison to 0.63 ng TGFβ. [b] No significant differences were 
 observed in PLOD2b mRNA expression between 1 and 20 ng TGFβ stimulations.
[A]
[B]                                           PLOD2b gene expression
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Discussion
Fibrosis is characterized by an accumulation of collagen. In fibrotic lesions, collagen  contains 
an increased amount of pyridinoline cross-links. LH2b is known to induce the  formation 
of pyridinoline cross-links in collagen. Collagen containing pyridinoline cross-links is 
less susceptible to enzymatic degradation, which may lead to collagen accumulation (18). 
 Furthermore, the amount of pyridinoline cross-links in the matrix is an  important criterion 
in assessing the irreversibility of fibrosis (18). 
In previous studies, we have shown that TGFβ-induced irreversible fibrosis, whereas 
 CTGF-induced transient fibrosis (6, 12, 17). In this study, we demonstrated that both LH2b 
mRNA and LH2 protein expression were strongly elevated by TGFβ and not by CTGF in 
osteoarthritic human synovial fibroblasts. Van der Slot et al. studied the effect of TGFβ on 
skin fibroblasts and also found an induction of LH2b mRNA expression. This increase of 
LH2b was accompanied by an increase in pyridinoline cross-links (25). Since TGFβ was 
increased in the synovial fluid of osteoarthritis patients, an induction of LH2b and an increase 
of pyridinoline cross-links in the synovium is plausible (3). Elevated amounts of pyridinoline 
cross-links were reported in different fibrotic diseases: for instance, in systemic sclerosis, 
alcoholic cirrhosis and glomerulosclerosis (18). We propose that this induction of LH2b and 
therefore an increase in pyridinoline cross-links, may be responsible for  persistent fibrosis 
in osteoarthritis. Besides LH2b, TGFβ also induced CTGF mRNA expression in  human 
synovial fibroblasts. Some researchers propose that CTGF is necessary for the persistence 
of fibrosis, since they found that only subcutaneous injection of TGFβ plus CTGF into the 
tissue of newborn mice produced long-term fibrotic tissue (15). However, in our previous 
paper, we showed that TGFβ-induced persistent fibrosis for at least 3 months, whereas 
CTGF-induced fibrosis was resorbed by day 28 (17). CTGF might still be an important factor 
in the maintenance of TGFβ-induced fibrosis but in itself it was not capable of producing 
persistent fibrosis. TGFβ alone could be sufficient to produce persistent fibrosis due to the 
collagen accumulation and subsequent cross-linking by LH2b. However, since CTGF is 
always expressed by exposure to TGFβ, we cannot rule out an additional role for CTGF in 
TGFβ-dependent persistent fibrosis. Since we proposed that LH2b is the factor responsible 
for the persistence of TGFβ-induced synovial fibrosis in osteoarthritis, we investigated how 
LH2b expression was regulated via TGFβ signaling. This knowledge could be of considerable 
importance for finding a target to prevent the induction of LH2b and thereby persistent 
fibrosis in osteoarthritis. 
We investigated whether LH2b, CTGF and COL1A1 mRNA expression were specific 
for ALK4/5/7 or ALK1/2/3/6 signaling. Dorsomorphin and SB-505124 were used to  inhibit 
the  kinase activity of ALK1/2/3/6 and ALK4/5/7, respectively. Dorsomorphin  completely 
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 inhibited the basal “ALK1/2/3/6-mediated” Smad1/5/8P level but could only slightly  reduce 
TGFβ- induced Smad1/5/8P. This minor reduction by dorsomorphin might be due to the 
abolished basal Smad1/5/8P level, since the TGFβ-induced Smad1/5/8P signal was an 
 accumulation of both the basal Smad1/5/8P and TGFβ-induced Smad1/5/8P. This suggests 
that ALK1/2/3/6 kinase activity is not required for TGFβ-induced Smad1/5/8P in human 
synovial fibroblasts. Blocking the ALK4/5/7 kinase activity with SB-505124 inhibited both 
 TGFβ-induced Smad2/3P and Smad1/5/8P. This indicated that TGFβ-induced Smad2/3P 
and Smad1/5/8P were both dependent on ALK4/5/7 kinase activity in human synovial fibro-
blasts. This could potentially explain why TGFβ-induced Smad1/5/8P could not be blocked 
by dorsomorphin. Involvement of TGFβ-mediated ALK4/5/7 kinase activity in both Smad2/3 
and Smad1/5/8 phosphorylation has also been shown in C2C12 and HepG2 cells, where 
dorsomorphin did not abolish TGFβ-induced Smad1/5/8P, similar to our data (10). Blocking 
either ALK1/2/3/6 or ALK4/5/7 kinase activity in the human  synovial fibroblasts prevented 
the induction of COL1A1 and CTGF after TGFβ stimulation. Since dorsomorphin is unable 
to abolish TGFβ- induced Smad1/5/8 phosphorylation, the inhibition of COL1A1 and CTGF 
by dorsomorphin could very well be reliant on a non-Smad- dependent pathway. Non-Smad 
pathways that can be blocked by dorsomorphin are the MAPKs p38, ERK1/2, Akt and the Src 
pathway (23, 26). In different articles and for different cell types, including fibroblasts, it has 
been shown that the Src path way is necessary for TGFβ- related CTGF induction. Therefore, 
blockage of this non-Smad pathway might clarify the  inhibition of CTGF by dorsomorphin 
that we found in the human synovial fibroblasts (27-29). Furthermore, it has been shown 
that CTGF was required for TGFβ-induced COL1A1 expression  (30, 31). Since we blocked 
TGFβ-related CTGF induction by dorsomorphin, this would also prevent TGFβ-related 
 CTGF-dependent COL1A1 elevation. For sclero derma fibro blasts, it has been reported that 
the TGFβR1- dependent induction of  COL1A1 and CTGF did not involve Smad2/3 activation 
but was mediated by ALK1/Smad1 and ERK1/2 pathways (32). However, in Smad3- knockout 
fibroblasts, it was shown that normal dermal fibroblasts required Smad3 for TGFβ-induced 
CTGF expression (33). This difference between normal and scleroderma fibroblasts was 
thought to be due to the existence of an alternative TGFβ-dependent, Smad3-independent 
signaling pathway that might operate in chronic stages of SSc fibrosis. Thus, depending on the 
cell type and stage, the signaling by TGFβ might be different. Our results show that in osteo-
arthritic human synovial fibroblasts both the ALK4/5/7 and ALK1/2/3/6 route are required 
for induction of COL1A1 and CTGF. 
Similar to COL1A1 and CTGF gene expression, inhibition of ALK4/5/7 kinase activity 
prevented TGFβ-induced LH2b mRNA expression. Strikingly, LH2b was still significantly 
upregulated by TGFβ when the ALK1/2/3/6 kinase activity was blocked. Furthermore, over-
expressing caALK5 induced both LH2b mRNA expression and LH2 protein expression, 
 whereas caALK1 did not alter LH2b expression. Whereas COL1A1 and CTGF depend on 
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both the ALK4/5/7 and ALK1/2/3/6 route, LH2b only required the ALK4/5/7 route. These 
results  suggest that TGFβ-induced LH2b is governed by the canonical TGFβ type 1  receptor 
ALK5 and does not require ALK1 signaling. Since we found a shift towards Smad1/5/8P 
at higher TGFβ concentrations we expected lower LH2b mRNA expression at higher 
TGFβ  concentrations due to the diminished Smad2/3P, in comparison to the lower TGFβ 
 concentrations. The  effects observed on western blot were after 30 min of TGFβ stimulation, 
whereas the samples for Q-PCR were stimulated for 24 h. Initially, we thought this might 
explain the lack of changes in LH2b mRNA expression. However, we repeated the experiment 
with shorter stimulations with TGFβ (data not shown), which did not show any change in 
LH2b expres sion. A possible explanation can be that a limited amount of Smad2/3 signaling 
was sufficient to fully induce LH2b expression. 
Since we propose that LH2b is responsible for the persistence of fibrosis in osteo arthritis, 
blocking ALK5 may prevent persisted fibrosis. This is supported by a study that showed that 
progressive TGFβ1–induced pulmonary fibrosis in rats was inhibited when an ALK5  kinase 
activity inhibitor was administered at the time of initiation of fibrogenesis. Furthermore, they 
showed that blocking the ALK5 kinase activity even blocked progressive fibrosis in rats with 
established fibrosis (34). Although blocking LH2b by ALK5  inhibition sounds promising 
for prevention of fibrosis, in joints with osteoarthritis, extreme caution should be taken as 
ALK5 is indispensable in maintenance of cartilage. As such, blocking ALK5 in general will 
have  adverse effects on the cartilage causing increased MMP-13 expression and decreased 
 aggrecan and collagen type II synthesis by the chondrocytes. This will result in loss of homeo-
stasis of the articular cartilage (11). 
In this study, we showed that LH2b was induced by TGFβ in osteoarthritic human  synovial 
fibroblasts. Overexpressing ALK5 induced LH2b, whereas blocking the ALK5  kinase activity 
prevented TGFβ-induced LH2b expression. In contrast to COL1A1 and CTGF, LH2b did not 
require both ALK1/2/3/6 and ALK5 signaling but relies on ALK5 signaling alone. In osteo-
arthritis, TGFβ is elevated in the knee joint, potentially causing elevated LH2b  expression. 
LH2b increases the formation of pyridinoline cross-links in collagen, which are  commonly 
found elevated in different fibrotic diseases. Therefore, TGFβ-induced LH2b may be 
 responsible for the persistence of fibrosis in osteoarthritis. Blocking of LH2b in osteoarthritis 
may prevent the formation of the pyridinoline cross-links and consequently the formation of 
 persistent fibrosis and chronic joint stiffness.
105
    
Chapter 5
Acknowledgments 
The authors would like to thank MJ Goumans and Peter ten Dijke (Leiden University Medical 
Center). This study was supported by a grant from the Dutch Arthritis Association (grant NR 
09-1-403).
References
1 Hill CL, Hunter DJ, Niu J, Clancy M, Guermazi A, Genant H, Gale D, Grainger A, 
Conaghan P, Felson DT (2007) Synovitis detected on magnetic resonance imaging and 
its relation to pain and cartilage loss in knee osteoarthritis. Ann Rheum Dis 66:1599–
1603 
2 Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 
18:816–827
3 Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor-beta 
in human disease. N EnglJ Med342:1350–1358
4 Gordon KJ, Blobe GC (2008) Role of transforming growth factor-beta superfamily 
signaling pathways in human disease. Biochim Biophys Acta 1782:197–228 
5 Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn 
MB, Thorgeirsson SS (1995) Hepatic expression of mature transforming growth factor 
beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92: 
2572–2576 
6 Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB (2003) Reduction 
of osteophyte formation and synovial thickening by adenoviral overexpression of 
transforming growth factor beta / bone morphogenetic protein inhibitors during 
experimental osteoarthritis. Arthritis Rheum 48:3442–3451 
7 ten Dijke P, Arthur HM (2007) Extracellular control of TGFbeta signalling in vascular 
development and disease. Nat Rev Mol Cell Biol 8: 857–869 
8 Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P(2002)
Balancing the activation state of the endothelium via two distinct TGF-beta type I 
receptors. EMBO J 21:1743–1753 
9 Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, Wang XF (2009) TGFbeta-
stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the 
promigratory TGFbeta switch. EMBOJ 28:88–98 
106
10 Wrighton KH, Lin X, Yu PB, Feng XH (2009) Transforming growth factor beta can 
stimulate Smad1 phosphorylation independently of bone morphogenic protein 
receptors. J Biol Chem 284: 9755–9763 
11 Blaney Davidson EN, Remst DF, Vitters EL, van Beuningen HM, Blom AB, Goumans 
MJ, van den Berg WB, van der Kraan PM (2009) Increase in ALK1/ALK5 ratio as 
a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. J 
Immunol 182: 7937–7945 
12 Bakker AC, van de Loo FA, van Beuningen HM, Sime P, van Lent PL, van der Kraan 
PM, Richards CD, van den Berg WB (2001) Overexpression of active TGF-beta-1 in 
the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte 
formation. Osteoarthr Cartil 9:128–136 
13 Blaney Davidson EN, Vitters EL, Mooren FM, Oliver N, Berg WB, van der Kraan PM 
(2006) Connective tissue growth factor/CCN2 over- expression in mouse synovial 
lining results in transient fibrosis and cartilage damage. Arthritis Rheum 54:1653–1661 
14 Bonniaud P, Margetts PJ, Kolb M, Haberberger T, Kelly M, Robertson J, Gauldie J 
(2003) Adenoviral gene transfer of connective tissue growth factor in the lung induces 
transient fibrosis. Am J Respir Crit Care Med 168:770–778 
15 Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, 
Nakanishi T, Takehara K (1999) Role and interaction of connective tissue growth factor 
with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J 
Cell Physiol 181:153–159 
16 van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB (1993) Does TGF-
beta protect articular cartilage in vivo? Agents Actions Suppl 39:127–131 
17 Remst DF, Blaney Davidson EN, Vitters EL, Blom AB, Stoop R, Snabel JM, Bank RA, 
van den Berg WB, van der Kraan PM (2013) Osteoarthritis-related fibrosis is associated 
with both elevated pyridinoline cross-link formation and lysyl hydroxylase 2b expres- 
sion. Osteoarthr Cartil 21:157–164 
18 van der Slot AJ, Zuurmond AM, van den Bogaerdt AJ, Ulrich MM, Middelkoop E, Boers 
W, Karel Ronday H, DeGroot J, Huizinga TW, Bank RA (2004) Increased formation of 
pyridinoline cross-links due to higher telopeptide lysyl hydroxylase levels is a general 
fibrotic phenomenon. Matrix Biol 23:251–257 
19 Wu J, Reinhardt DP, Batmunkh C, Lindenmaier W, Far RK, Notbohm H, Hunzelmann 
N, Brinckmann J (2006) Functional diversity of lysyl hydroxylase 2 in collagen synthesis 
of human dermal fibroblasts. Exp Cell Res 312:3485–3494 
20 Pornprasertsuk S, Duarte WR, Mochida Y, Yamauchi M (2004) Lysyl hydroxylase 
2b directs collagen cross-linking pathways in MC3T3- E1 cells. J Bone Miner Res 
19:1349–1355 
107
    
Chapter 5
21 van der Slot AJ, Zuurmond AM, Bardoel AF, Wijmenga C, Pruijs HE, Sillence DO, 
Brinckmann J, Abraham DJ, Black CM, Verzijl N, DeGroot J, Hanemaaijer R, 
TeKoppele JM, Huizinga TW, Bank RA (2003) Identification of PLOD2 as telopeptide 
lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 278:40967–40972 
22 Sciaky D, Brazer W, Center DM, Cruikshank WW, Smith TJ (2000) Cultured human 
fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein 
synthesis through a caspase-3-dependent mechanism. J Immunol 164:3806–3814 
23 Boergermann JH, Kopf J, Yu PB, Knaus P (2010) Dorsomorphin and LDN-193189 
inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int J Biochem 
Cell Biol 42:1802–1807 
24 DaCosta Byfield S, Major C, Laping NJ, Roberts AB (2004) SB-505124 is a selective 
inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. 
Mol Pharmacol 65:744–752 
25 van der Slot AJ, van Dura EA, de Wit EC, De Groot J, Huizinga TW, Bank RA, 
Zuurmond AM (2005) Elevated formation of pyridinoline cross-links by profibrotic 
cytokines is associated with enhanced lysyl hydroxylase 2b levels. Biochim Biophys 
Acta 1741:95–102 
26 Vogt J, Traynor R, Sapkota GP (2011) The specificities of small molecule inhibitors of 
the TGFss and BMP pathways. Cell Signal 23:1831–1842
27 Arnott JA, Zhang X, Sanjay A, Owen TA, Smock SL, Rehman S, DeLong WG, Safadi FF, 
Popoff SN (2008) Molecular requirements for induction of CTGF expression by TGF-
beta1 in primary osteo- blasts. Bone 42:871–885 
28 Kroening S, Solomovitch S, Sachs M, Wullich B, Goppelt-Struebe M (2009) Regulation 
of connective tissue growth factor (CTGF) by hepatocyte growth factor in human 
tubular epithelial cells. Nephrol Dial Transplant 24:755–762 
29 Zhang X, Arnott JA, Rehman S, Delong WG Jr, Sanjay A, Safadi FF, Popoff SN (2010) 
Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts. 
J Cell Physiol 224:691–70
30 Fuchshofer R, Birke M, Welge-Lussen U, Kook D, Lutjen-Drecoll E (2005) Transforming 
growth factor-beta 2 modulated extracellular matrix component expression in cultured 
human optic nerve head astrocytes. Investig Ophthalmol Vis Sci 46:568–578 
31 Nakerakanti SS, Bujor AM, Trojanowska M (2011) CCN2 is required for the TGF-beta 
induced activation of Smad1-Erk1/2 signaling net- work. PLoS ONE 6:e21911
32 Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M (2007) Transforming 
growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via 
activation of Smad1 and ERK1/2 pathways. J Biol Chem 282:10405–10413 
108
33 Mori Y, Chen SJ, Varga J (2003) Expression and regulation of intracellular SMAD 
signaling in scleroderma skin fibroblasts. Arthritis Rheum 48:1964–1978 
34 Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy 
A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J (2005) Progressive 
transforming growth factor beta1-induced lung fibrosis is blocked by an orally active 
ALK5 kinase inhibitor. Am J Respir Crit Care Med 171:889–898
109
    
Chapter 5
110
111
Chapter 6
Concluding remarks
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Synovial fibrosis is a synoviopathy that affects more that 50% of the OA patients and is an 
 important cause for joint stiffness in OA. In this thesis we have investigated which factor is 
responsible for OA-related fibrosis. TGFβ is known for its fibrotic properties and is found 
elevated in the synovial fluid of OA patients. Because inhibition of TGFβ, due to its role in 
cartilage maintenance, will have severe side effects we searched for genes downstream of 
TGFβ which may be involved in synovial fibrosis and could be a target for therapy. The most 
promising gene, looking both at side effects and on its possible contribution to fibrosis, that 
came out of our exploration was PLOD2. 
We found PLOD2 to be elevated in OA fibroblasts stimulated with TGFβ and in the syno-
vium of mice with TGFβ-induced fibrosis, but not in conditions with the pro-fibrotic growth 
factor CTGF. Because CTGF-induces transient fibrosis whereas TGFβ-induced fibrosis is 
persistent, this is highly suggestive for a key role of PLOD2 in the persistence of fibrosis. 
 Especially because PLOD2 encodes for the collagen cross-linking enzyme lysyl hydroxylase 
2b (LH2b), which activity results in the formation of pyrodinoline cross-links. These pyridi-
noline cross-links make collagen harder to degrade and more rigid and are present at elevated 
levels in different fibrotic tissues. We found in an experimental OA model that is  accompanied 
by fibrosis, besides elevated PLOD2 expression levels (both on gene expression and protein 
level), an increase in the amount of pyridinoline cross-links per triple helix. 
For that reason it is plausible that PLOD2 is responsible for OA-related persistent  fibrosis. 
Most importantly, we found that PLOD2 was also increased in the synovium of patients 
with end-stage OA (Figure 1). It would have been convenient if PLOD2 would have been 
 regulated via TGFβ/ALK1 signaling, because ALK1 signaling can be deleterious for  cartilage 
and  therefore could potentially be blocked without negative side effects in an OA joint. 
 Unfortunately, we found that LH2b was regulated via TGFβ/ALK5 signaling. Blocking ALK5 
would be disastrous for the cartilage because this leads to elevated MMP13 expression and 
therefore cartilage breakdown. 
The question that still remains after completion of this thesis is whether blocking the 
 induction of LH2 in OA indeed will prevent or even reverse OA-related synovial fibrosis. 
For clinical application it is very important to make the distinction whether inhibition of 
LH2b can only prevent or also reverse OA-related fibrosis. When inhibition of LH2 can only 
prevent fibrosis, exclusively patients with onset OA, before fibrosis occurs, could be treated. 
 However, we presume that blocking LH2 in OA will both prevent and reverse OA-related 
 synovial  fibrosis, because the collagen will not be longer highly cross-linked. Therefore, in 
time the collagen will be degraded by the elevated MMP activity in the OA joints. We expect 
that solving fibrosis in OA-patients will contribute to reduction of joint stiffness and even 
joint pain. This since the fibrotic synovium may impair joint movement by increasing the 
tension of the joint capsule and thereby also limiting smooth joint movement. 
Next to potentially solve OA-related fibrosis, inhibition of LH2b could also be promising 
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to prevent arthrofibrosis, a disease whereby knee motion is limited due to massive fibrosis 
after joint injury or surgery.    
Unfortunately, we could not find an effective method to inhibit LH2 activity within in the 
time span of this project. Because, LH2 is intracellular and no small molecule inhibitors are 
available LH2 is a difficult target to inhibit. However, it still our goal to inhibit LH2 and we 
want to achieve this in the near future in experimental OA models, and if successful, in OA 
patients. 
Figure 1. Schematic overview of our main findings and the proposed effect of PLOD2 on the synovium.
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Nederlandse samenvatting 
Osteoarthritis (OA) wordt gekenmerkt door kraakbeenschade, osteofytvorming en synoviale 
fibrose. Deze fibrose maakt het synovium dikker en stijver waardoor het gewricht minder 
bewegelijk wordt. Daarom wordt synoviale fibrose gezien als een van de hoofdoorzaken van 
gewrichtsstijfheid. Naar schatting heeft het merendeel van de OA patiënten last van synoviale 
fibrose. 
TGFβ dat verhoogd aanwezig is in het gewricht tijdens OA staat bekend als de factor 
 verantwoordelijk voor fibrose (hoofdstuk 1). In eerdere studies hebben we laten zien dat het 
verhoogd tot expressie brengen van TGFβ in muizen kniegewrichten resulteert in fibrose, 
waar het inhiberen van TGFβ in experimentele OA in muizen juist fibrose voorkomt. Helaas 
zal het blokken van TGFβ in een OA gewricht te veel negatieve effecten hebben, aangezien 
TGFβ nodig is voor het onderhoud van het kraakbeen. Daarom hebben we gezocht naar een 
eiwit/gen lager in de TGFβ signaalroute dat verantwoordelijk is voor de synoviale fibrose 
(hoofdstuk 2). Om dit eiwit/gen te vinden hebben we de expressie van genen gemeten die 
 coderen voor eiwitten die betrokken zijn bij de opbouw en afbraak van de extracellulaire 
matrix (ECM) of deze kunnen beïnvloeden. Deze genen hebben we gemeten in  synoviale 
 fibroblasten gestimuleerd met TGFβ, in synovium van muizen met TGFβ-geïnduceerde 
 fibrose en collagenase-geïnduceerde OA, maar ook in het synovium van patiënten met eind-
stadium OA. We vonden dat de genen PLOD2, LOX, COL1A1, Col5A1 en TIMP1 hoger tot 
expressie kwamen in al deze OA/fibrotische condities in vergelijking met de controles. 
Vervolgens hebben we TGFβ geïnduceerde “blijvende” fibrose vergeleken met CTGF 
 geïnduceerde “tijdelijke” fibrose (hoofdstuk 3). Dit omdat een verschil in genregulatie  tussen 
TGFβ en CTGF geïnduceerde fibrose de factor verantwoordelijk voor de persistentie van 
TGFβ geïnduceerde fibrose kan zijn. Het meest opmerkelijke verschil tussen CTGF- en 
TGFβ- geïnduceerde fibrose was de expressie van PLOD2. PLOD2 codeert voor het enzym 
lysyl hydroxylase 2b (LH2b) dat zorgt voor een verhoging van het aantal pyridinoline kruis-
verbindingen tussen de collageen drievoudige helixen. Deze kruisverbindingen maken het 
collageen moeilijker afbreekbaar voor enzymatische reacties, wat resulteert in accumulatie 
van collageen en daardoor bijdragen aan fibrose. We hebben gemeten of deze pyridinoline 
kruisverbindingen ook daadwerkelijk verhoogd zijn in het synovium van muizen met col-
lagenase-geïnduceerde OA dat gepaard gaat met fibrose en waar LH2b zowel op gen als op 
eiwit niveau verhoogd is. We vonden dat er vanaf dag 21 na artrose inductie inderdaad een 
 verhoging aantoonbaar was van het aantal pyridinoline kruisverbindingen per collageen 
drievoudige helix. Dit maakt PLOD2/LH2 een zeer interessant doelwit om te remmen bij 
 synoviale fibrose tijdens OA. Om te vast te stellen of LH2b inderdaad verantwoordelijk is voor 
de persistentie van fibrose hebben we LH2b in combinatie met CTGF verhoogd tot expressie 
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gebracht in muizenknietjes (hoofdstuk 4). Dit om te testen of LH2b, CTGF geïnduceerde 
 fibrose persistent kan maken. Helaas konden we door technische problemen in dit experi-
ment geen valide conclusies trekken.
 Tevens hebben we onderzocht via welke TGFβ signaalroute, ALK1 of ALK5, LH2 
 gereguleerd word (hoofdstuk 5). Doormiddel van overexpressie en remming studies hebben 
we aangetoond dat LH2 gereguleerd wordt via TGFβ/ALK5 signalering. Aangezien ALK5 de 
route van TGFβ is die zorgt voor het onderhoud van het kraakbeen is het niet verstandig deze 
te onderdrukken in een gewricht van een OA patiënt. Daarom zal er naar een andere manier 
gekeken moeten worden om LH2b te remmen.
In dit proefschrift hebben we gezocht naar de oorzaak van OA gerelateerde synoviale 
 fibrose. We hebben gevonden dat LH2b in verscheidene fibrotische/OA gerelateerde condities 
sterk verhoogd is ten opzichte van de controles. Ook hebben we gevonden dat de pyridi noline 
kruisverbindingen die door LH2b mogelijk gemaakt worden verhoogd zijn bij experi mentele 
OA. Deze pyridinoline kruisverbindingen zijn verhoogd aangetroffen in verschillende fibro-
tische ziekten. Dit toont de potentie aan van het remmen van LH2b om synoviale fibrose 
te voorkomen. Daarom is het een aantrekkelijke optie om LH2b te remmen tijdens OA om 
te onderzoeken of dit een nieuwe behandeling kan worden om gewrichtsstijfheid bij OA 
 patiënten te verminderen.  
118
List of abbreviations
A disintegrin and metalloproteinase domain 12   ADAM12
Activin receptor-like kinase     ALK
Adenovirus       Ad
Collagen, type x, alpha x      COLxAx
Complementary DNA      cDNA
Connective tissue growth factor     CTGF
Constitutively active      ca
Dorsomorphin      DM
Extracellular matrix      ECM
Fat-conditioned medium      FCM
high-performance liquid chromatography    HPLC
Human synovial fibroblasts    hSF
Intra-articularly       i.a.
Lysyl hydroxylase      LH
Lysyl oxidase       LOX
Matrix metalloproteinases      MMP
osteoarthritis       OA
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2   PLOD2
Prostaglandin F2α      PGF2α
Quantitative PCR      Q-PCR
SB-505124       SB-5
Tissue inhibitor of metalloproteinase 1    TIMP-1
Transforming growth factor-beta     TGFß
Unilateral ureteral obstruction    UUO
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